Open Access Full Text Article

Vitamin D deficiency and the risk of tuberculosis: a meta-analysis

Shao-Jun Huang¹ Xian-Hua Wang² Zhi-Dong Liu¹ Wen-Li Cao³ Yi Han¹ Ai-Guo Ma² Shao-Fa Xu¹

¹Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China; ²Department of Nutrition and Food Hygiene, Institute of Human Nutrition, Medical College of Qingdao University, Qingdao, People's Republic of China; ³Department of Pulmonary Medicine, Beijing Geriatric Hospital, Beijing, People's Republic of China

Correspondence: Shao-Fa Xu Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, No 97 Machang, Tongzhou District, Beijing, People's Republic of China Tel +86 10 8950 9326 Email shaofaxu@yahoo.com



Background and aim: To conduct meta-analyses of all published studies on various aspects of association between vitamin D and tuberculosis (TB).

Methods: PubMed and Web of Knowledge were searched for all properly controlled studies on vitamin D and TB. Pooled odds ratio, mean difference or standardized mean difference, and its corresponding 95% confidence interval were calculated with the Cochrane Review Manager 5.3.

Results: A significantly lower vitamin D level was found in TB patients vs controls; vitamin D deficiency (VDD) was associated with an increased risk of TB, although such an association was lacking in the African population and in the human immunodeficiency virus-infected African population. A significantly lower vitamin D level was found in human immunodeficiency virus-TB-coinfected African patients receiving antiretroviral treatment who developed TB-associated immune reconstitution inflammatory syndrome vs those who did not develop TB-associated immune reconstitution inflammatory syndrome. VDD was associated with an increased risk of developing active TB in those subjects with latent TB infection and with an increased risk of tuberculin skin test conversion/TB infection subjects did not reach statistical significance, indicating that VDD was more likely a risk factor than a consequence of TB. This concept was further strengthened by our result that anti-TB treatment did not affect vitamin D level in TB patients receiving the treatment.

Conclusion: Our analyses revealed an association between vitamin D and TB. VDD is more likely a risk factor for TB than its consequence. More studies are needed to determine whether vitamin D supplementation is beneficial to TB prevention and treatment.

Keywords: vitamin D, vitamin D deficiency, tuberculosis, 25-hydroxyvitamin D, metaanalysis

Introduction

Tuberculosis (TB) remains a major public health problem globally. It was estimated that there were 8.7 million reported new TB cases and that 1.4 million people died from TB in 2011.¹ Various factors that could possibly affect the incidence and progression of TB have been reported, one of them is vitamin D deficiency (VDD).^{1–6} Exposure to sunlight is the main source of vitamin D for human and induces the conversion of 7-dehydrocholesterol to vitamin D3 via previtamin D3 in the skin.⁷ Vitamin D3 is then converted to 25-hydroxyvitamin D (25(OH)D) in the liver and is further converted to the bioactive form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in the kidney.⁷ Studies have found that 1,25(OH)2D3 binds to vitamin D receptor (VDR), activates VDR signaling, and induces a series of antimicrobial responses such as induction of autophagy, phagolysosomal fusion, release and activation of the antimicrobial peptide cathelicidin, and killing of intracellular *Mycobacterium tuberculosis*.^{7–9}

Drug Design, Development and Therapy 2017:11 91-102

© 2017 Huag et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraph 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php).

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 208.53.112.118 on 30-Dec-2016 For personal use only.

Numerous studies have been conducted to study whether VDD was associated with TB; however, they produced inconsistent and varying results.^{1-6,10-12} There has been one meta-analysis on association between VDD and TB, and it concluded that a lower serum vitamin D level was associated with a higher risk of active TB.¹³ However, it was conducted in 2008 and did not include numerous later studies, and further it did not perform a subgroup analysis based on factors such as ethnicity.

In this study, we performed meta-analyses comparing serum vitamin D levels in TB cases vs controls and on association between VDD and risk of TB with subgroup analysis based on the ethnicity of the study population in order to further elucidate the role of vitamin D level in TB pathogenesis in a larger population pool. Second, assuming VDD is indeed associated with TB, it is still undetermined whether VDD is one of the causes of TB or manifestation of the malnutrition status generally seen in TB patients.¹ In order to explore this question, we further examined the association between vitamin D level/VDD and risk of developing active TB in subjects with latent TB infection (LTBI)/household contacts of TB patients and also the association between VDD and tuberculin skin test (TST) conversion/TB infection conversion (TBIC). An additional analysis was also performed on the effect of anti-TB treatment on vitamin D level in TB subjects for the same purpose. Third, since human immunodeficiency virus (HIV)-infected subjects are more susceptible to TB and have greater mortality and morbidity caused by TB,14 to further clarify whether vitamin D played any role in occurrence and deterioration of TB in HIV-infected subjects, we also analyzed the association between vitamin D level/ VDD and TB in HIV-infected subjects and the association between vitamin D level and risk of developing TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) in HIV-TB-coinfected patients receiving antiretroviral therapy (ART). Finally, although serum 25(OH)D is the commonly used measure of vitamin D status in a subject,⁷ 1,25(OH)2D3 is the actual bioactive form of vitamin D that induces antimicrobial response,⁷ and so we also performed a meta-analysis on the association between 1,25(OH)2D3 and TB in order to determine whether there was any change of 1,25(OH)2D3 level in TB subjects compared to control without TB.

Methods

92

Search strategy, inclusion and exclusion criteria, and data extraction

PubMed/Medline and Web of Science (Web of Knowledge) databases were searched to identify all studies relating to vitamin D and TB using the following search terms: "vitamin D", "VDD", "hypovitaminosis D", "tuberculosis", "TB", "25-hydroxyvitamin D", and "1,25-dihydroxyvitamin D".

All properly controlled studies published in English on vitamin D and TB were potentially eligible for inclusion in our meta-analysis. We excluded reviews, meeting abstracts, and case-only studies.

Relevant data from each included study were extracted. Among the data extracted, relevant group meanvalues (standard deviations, SDs) were extracted from each included study whenever possible. When relevant values were presented only as median (interquartile range), mean (SD) was approximated as median (interquartile range/1.35);¹⁵ when relevant values were presented only as median (range), mean (SD) was approximated as median (range/4);¹⁶ when relevant values were presented only as median (range/3);¹⁶ when relevant values were presented only as mean values (standard errors, SEs), SD was extracted as SE × square root of sample size;¹⁷ and when relevant values were presented only as meanvalues (confidence intervals, CIs), SD was extracted as square root of sample size × (upper limit – lower limit)/(2× *Y*), where *Y* is the *t* value from a size equal to sample size minus 1.¹⁷

Quality of the studies

Each study's adequacy in three key areas (methodological, clinical, and statistical) was evaluated first. Then each study was screened with the Newcastle–Ottawa Scale.¹⁸

Statistical analysis

Cochrane Review Manager (RevMan 5.3, Copenhagen, Denmark, The Nordic Cochrane Centre) was used to perform all statistical analysis. Continuous outcomes were analyzed using mean difference (MD) or standardized MD (SMD), while dichotomous outcome was analyzed using pooled odds ratio (OR). Pooled OR and MD/SMD with their corresponding 95% CI were calculated with a random-effect model because this model assumes a genuine diversity in the results caused by between-studies heterogeneity and incorporates a between-studies variance into the calculation accordingly.¹⁹ The Z test was used to assess the statistical significance of the pooled OR and MD/SMD. Betweenstudies heterogeneity was assessed with the Cochran Q statistic-based chi-square (χ^2) test,²⁰ and I^2 index was the tool used to assess the heterogeneity, where a I^2 value around 25%, 50%, and 75% indicated a low, moderate, and large heterogeneity, respectively.²¹ Finally, if no heterogeneity was found using the random-effect model ($I^2=0$), data were analyzed again using a fixed-effect model. Statistical significance was considered with a P-value of <0.05, except for the Q statistic where a P-value of <0.10 indicated statistically significance.


Subpopulation analysis was performed according to the ethnicity of the subjects. In addition, funnel plots were used to evaluate the publication bias in each meta-analysis.

Results Eligible studies and characteristics of the studies

Figure 1 illustrates our search process and results. From a total of 723 potentially eligible articles, 685 were excluded because they were irrelevant to our topic here, reviews, meeting abstracts, or case-only studies, or contained no detailed data needed for our meta-analysis. A total of 38 articles were included in our meta-analysis.^{1,2,4,5,11,12,14,22-52}

Vitamin D level was significantly lower in TB patients vs controls, and VDD was associated with an increased risk of TB

A total of 25 studies with 3,599 TB cases and 3,063 control subjects were included in our analysis of serum/plasma 25(OH)D level in TB patients vs control (Figure 2A).^{1,4,5,11,12,14,22–28,30,35–44,46} Our analysis with a random-effect model showed a significantly lower serum/plasma 25(OH)D level in TB patients vs controls (MD =–13.05; 95% CI =[-19.02, -7.08]; P < 0.0001; l^2 =96) (Figure 2A). Subgroup analysis showed similar result for the Asian population (MD =–14.64; 95% CI =[-20.15, -9.13]; P < 0.00001; l^2 =89); however, there was no such significant



Studies included in the meta-analysis of serum/plasma 25-hydroxyvitamin D (25(OH)D) level in tuberculosis (TB) patients vs control, and of vitamin D deficiency (VDD) and TB, N=21, and 23, respectively.

Studies included in the meta-analysis of serum 25(OH)D level in active TB subject vs latent TB infection (LTBI) subjects/household contacts of active TB patients, of VDD and number of LTBI subjects or household contacts of TB patients developing active TB, and of VDD and risk of tuberculin skin test (TST) conversion/TB infection conversion (TBIC), N=4, 5, and 3, respectively.

Studies included in the meta-analysis of serum 25(OH)D level in HIV-TB coinfected patients vs HIV patients without TB, of VDD and risk of TB in HIV-infected patients, and of 25(OH)D level and risk of developing TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) in HIV-TB co-infected patients receiving antiretroviral therapy (ART), N=4, 4, and 3, respectively.

Studies included in the meta-analysis of the effect of 1–4 months of anti-TB treatment on 25(OH)D level in TB patients, of the effect of a full course of anti-TB treatment on 25(OH)D level in TB patients, and of 25(OH)D level in TB patients after anti-TB treatment vs control without TB, N=3, 4, and 4, respectively.

Studies included in the meta-analysis of the level of serum/plasma 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in TB patients vs control, N=4

Figure I Flow diagram of the publication selection process.

Study or subgroup Asian		TB Mean	SD	Total	Control Mean	SD	Total	Weight (%)	Mean difference IV, random, 95% CI	Year	Mean difference IV, random, 95% Cl
Grange et al ²³		65.75	21.69	40	69.5	19.12	38	3.6	-3.75 (-12.81, 5.31)	1985	-+
Davies et al ²⁶		69.5	24.5	51	95.5	29.25	51	3.5	-26.00 (-36.47, -15.53	1988	
Chan et al ²⁷		46.5	18.5	22	52.25	15.75	23	3.5	-5.75 (-15.81, 4.31)	1994	
Wilkinson et al4		12	10.74	103	17	10.96	42	3.9	-5.00 (-8.91, -1.09)	2000	-
Sasidharan et al ²⁸		26.75	18.13	35	48.5	30.63	16	3.1	-21.75 (-37.92, -5.58)	2002	
Rathored et al ³⁸ MDR-TB cases	s	13.5	10	354	34.9	26.2	205	3.9	-21.40 (-25.13, -17.67	2012	+
Koo et al ³⁷		34.75	24.07	116	33	17.96	86	3.8	1.75 (-4.05, 7.55)	2012	+
Chaudhary et al ³⁹ diabetic case	es	39.9	32.18	40	48.55	28.3	46	3.3	-8.65 (-21.55, 4.25)	2013	
Chaudhary et al ³⁹ cases withou	ut diabetes	40.28	22.9	30	73.68	45.72	39	3.0	-33.40 (-49.92, -16.88	2013	
Kim et al55		33	21.58	165	46.75	20.83	197	3.9	-13.75 (-18.14, -9.36)	2013	+
Joshi et al ⁵⁶		37.14	19.05	25	76.19	28.57	25	3.3	-39.05 (-52.51, -25.59		(
Hong et al ⁴⁶		24.65	12.89	94	40.08	14.67	282	3.9	–15.43 (–18.55, –12.31	2014	÷
Subtotal (95% CI) Heterogeneity: τ^2 =72.43: γ^2 =9	6 49 df=11 (D	2~0.000	11. R=00	1,075			1,050	42.6	-14.64 (-20.15, -9.13)		•
Test for overall effect: $Z=5.21$ (~0.0000	51), 7 - 89	70							
African Davies et al ²⁴		39.75	18.13	15	65.5	22.13	15	3.2	-25.75 (-40.23, -11.27	1987	
Wejse et al⁵		78.3	22.6	362	85.3	34.8	494	3.9	-7.00 (-10.85, -3.15)	2007	+
Nansera et al14		60	27.5	50	70	27.5	50	3.5	-10.00 (-20.78, 0.78)	2011	
Martineau et al ³⁵		34.4	20.8	192	55	23	178	3.8	-20.60 (-25.08, -16.12	2011	+
Conesa-Botella et al ^{12,51} HIV-int		81	32.59	92	79	28.15	20	3.2	2.00 (-12.02, 16.02)	2012	-
Conesa-Botella et al ^{12,51} HIV-ur		78	22.22	27	71	20	23	3.4	7.00 (-4.71, 18.71)	2012	+
Steenhoff et al11		35.1	11.19	19	38.3	10.15	19	3.7	-3.20 (-9.99, 3.59)	2012	-+
Mastala et al43		59.7	28.48	161	84.2	40.6	157	3.7	-24.50 (-32.23, -16.77		
Friis et al40		110.9	35.7	1,223	84.4	25.6	347	3.9	26.50 (23.14, 29.86)	2013	-
Subtotal (95% Cl) Heterogeneity: τ²=468.91; χ²=	:389.17. df=8 ((P<0.00	001); <i> </i> ²=9	2,141 98%			1,303	32.4	-6.05 (-20.54, 8.43)		•
Test for overall effect: Z=0.82 (,, .								
Ethnicity unspecified		16	18	40	27.25	30 00	40	3.5	11 25 (22 22 0 47)	1095	
Davies et al ²² Davies et al ²⁵ patient group Oc		16	18 14	40 14	27.25	30.88 16	40	3.5	-11.25 (-22.33, -0.17)	1985	
Davies et al ²⁵ patient group Oc Davies et al ²⁵ patient group Ap		22	14 1 10	14 13	26.5	16 20.38	14 13	3.5	-4.50 (-15.64, 6.64)	1987	
Davies et al ²⁵ patient group Api Sita-Lumsden et al ³⁰		14.25 20.1	1.19 12.67	13 178	33.35 30.8	29.38 19.38	13 130	3.1 3.9	-19.10 (-35.08, -3.12) -10.70 (-14.52, -6.88)	1987 2007	
Sita-Lumsden et al ³⁰ Gray et al ³⁶		20.1 29.6	12.67	178	30.8 43.5	19.38 25.47	236	3.9 3.7	-10.70 (-14.52, -6.88) -13.90 (-21.25, -6.55)	2007	
Srinivasan et al44		67.45	10.71	22	117.43	18.4	230	3.6	-49.98 (-58.88, -41.08		
		55.58	17.03	105	73.18	22.23	255	3.9	-49.96 (-36.66, -41.06		
lftikhar ot al41						22.20	200	0.0	-17.00 (-21.00, -10.00	2013	
Iftikhar et al41 Subtotal (95% CI)		00.00	17.00				710	25.0	-18 15 (-27 28 -9 02)		▲
Subtotal (95% CI) Heterogeneity: τ^2 =129.43; χ^2 = Test for overall effect: Z=3.90 (69.26, df=6 (F			383 %			710	25.0	-18.15 (-27.28, -9.02)		•
Subtotal (95% Cl) Heterogeneity: t^2 =129.43; χ^2 =1 Test for overall effect: Z=3.90 (Total (95% Cl) Heterogeneity: t^2 =235.82; χ^2 =	69.26, df=6 (F (P<0.0001)	P<0.0000	01); <i>P</i> =91	383 % 3,599			710 3,063	25.0 100	-18.15 (-27.28, -9.02) -13.05 (-19.02, -7.08)	-1	◆ ↓ 00 -50 0 50
Subtotal (95% CI) Heterogeneity: r^2 =129.43; χ^2 = Test for overall effect: Z=3.90 (Total (95% CI)	69.26, <i>df</i> =6 (<i>F</i> (<i>P</i> <0.0001) 713.86, <i>df</i> =27 (<i>P</i> <0.0001)	P<0.0000	01); <i>P</i> =91 0001); <i>P</i> =	383 % 3,599						-1	00 -50 0 50 Lower Lower vit D in TB vit D in control
Subtotal (95% Cl) Heterogeneity: t^2 =129.43; χ^2 = Test for overall effect: Z=3.90 (Total (95% Cl) Heterogeneity: t^2 =235.82; χ^2 = Test for overall effect: Z=4.28 Test for subgroup differences: Study or subgroup	69.26, <i>df</i> =6 (<i>F</i> (<i>P</i> <0.0001) 713.86, <i>df</i> =27 (<i>P</i> <0.0001)	P<0.0000	01); <i>P</i> =91 0001); <i>P</i> = 8), <i>P</i> =0% C	383 % 3,599	Total	W (9	3,063 /eight	100 Odds i	-13.05 (-19.02, -7.08)	-1 ar	Lower Lower
Subtotal (95% CI) Heterogeneity: r^2 =129.43; χ^2 =1 Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: r^2 =235.82; χ^2 =1 Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian	(P<0.0001) (P<0.0001) (P<0.0001) (P<0.0001) $\chi^2=1.92, df=2$ TB Events	P<0.0000 7 (P<0.00 2 (P=0.38 Total	01); <i>P</i> =91 0001); <i>P</i> = B), <i>P</i> =0% C E	383 % 3,599 96% control vents	Total	(%	3,063 /eight %)	100 Odds M–H, r	–13.05 (–19.02, –7.08) ratio Ye andom, 95% Cl	ar	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% Cl) Heterogeneity: t^2 =129.43; χ^2 = Test for overall effect: Z=3.90 (Total (95% Cl) Heterogeneity: t^2 =235.82; χ^2 = Test for overall effect: Z=4.28 Test for subgroup differences: Study or subgroup Asian Grange et al ²³	$\frac{69.26}{(P<0.0001)}, \frac{df=6}{2} (P<0.0001)$ $\frac{713.86}{(P<0.0001)}, \frac{df=27}{2} (P<0.0001), \frac{df=2}{2} (P<0.000$	P<0.0000 7 (P<0.00 2 (P=0.38 Total 40	01); P=91 0001); P= B), P=0% <u>C</u> E 9	383 % 3,599 96% Control vents	Total 38	(% 4.	3,063 leight %) 2	100 Odds 1 M–H, r	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI	ar	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $t^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $t^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ²³ Wiklinson et al ⁴	(P<0.0001) (P<0.0001) (P<0.0001) (P<0.0001) $\chi^2=1.92, df=2$ TB Events 9 69	P<0.0000 7 (P<0.00 2 (P=0.38 Total 40 104	01); P=91 0001); P= 8), P=0% <u>C</u> <u>E</u> 9 1 [.]	383 1% 3,599 96% Control	Total 38 42	(% 4. 4.	3,063 (eight 6) 2 8	100 Odds (M–H, r 0.94 (0 5.56 (2	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI .33, 2.68) 16 .50, 12.35) 20	ar 85 00	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% Cl) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% Cl) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ⁴² Wikinson et al Sasidharan et al ²³ Martineau et al ¹³	$\begin{array}{c} 69.26, df=6 \ (F\\ (P<0.0001) \end{array}$ $\begin{array}{c} 713.86, df=27\\ (P<0.0001) \end{array}$ $\begin{array}{c} \chi^2=1.92, df=27\\ \textbf{TB}\\ \textbf{Events} \end{array}$ 9 69 16 60	P<0.0000 7 (P<0.00 2 (P=0.38 Total 40 104 35 84	01); P=91 0001); P= B), P=0% <u>C</u> E 9	383 1% 3,599 596% Control Events	Total 38 42 16 55	4. 4. 1. 5.	3,063 /eight %) 2 8 4 0	100 Odds M–H, r 0.94 (0 5.56 (2 27.92 (1.94 (0	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 1.33, 2.68) 16 5.0, 12.35) 20 1.55, 501.86) 20 25, 3.95) 20	ar 85 00 02 10	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or Study or Study or Saigharam et al ²⁸ Milkinson et al ⁴ Sasidharam et al ²⁸ Martineau et al ²⁸	$\begin{array}{c} 69.26, df=6 (F\\ (P<0.0001) \\ 713.86, df=27\\ (P<0.0001) \\ \chi^2=1.92, df=2 \\ \hline \\ $	P<0.0000 7 (P<0.00 8 (P=0.38 Total 40 104 35 84 166	0001); <i>P</i> =91 00001); <i>P</i> = 8), <i>P</i> =0% C E 9 1' 0 3 4	383 1% 3,599 596% Control Events 1	Total 38 42 16 55 219	(% 4. 4. 5. 3.	3,063 /eight 6) 2 8 4 0 8	Odds : M–H, r 0.94 (0 5.56 (2 27.92 1.94 (0 2.72 (0	-13.05 (-19.02, -7.08) ratio Ye andom, 95% Cl 33, 2.68) 19 .50, 12.35) 20 .55, 50.186) 20 .95, 3.95) 20 .81, 9.20) 20	ar 85 00 02 10 10	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or Subgroup Asian Grange et al ⁴³ Wikinson et al ⁴³ Martineau et al ⁴³ Ho-Pham et al ⁴² Ho-Pham et al ⁴²	$\begin{array}{c} 69.26, df=6 \ (F\\ (P<0.0001) \end{array}$ $\begin{array}{c} 713.86, df=27\\ (P<0.0001) \end{array}$ $\begin{array}{c} \chi^2=1.92, df=2 \end{array}$ $\begin{array}{c} TB\\ Events \end{array}$ $\begin{array}{c} 9\\ 69\\ 16\\ 60\\ 8\\ 42 \end{array}$	P<0.0000 7 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 116	001); <i>P</i> =91 00001); <i>P</i> = 8), <i>P</i> =0% C E 9 11 0 3 3 4 22	383 1% 3,599 :96% control vents 1 1 1	Total 38 42 16 55 219 86	(% 4. 4. 5. 3. 5.	3,063 /eight 6) 2 8 4 0 8 3	100 Odds (M-H, r 0.94 (0 5.56 (2 2.7.92 (1.94 (0 2.72 (0 1.47 (0	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI .33, 2.68) 16 .50, 12.35) 20 .155, 501.86) 20 .95, 3.95) 20 .80, 2.68) 20	ar 85 00 02 10 10 12	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ²³ Wikinson et al ⁴³ Ho-Pham et al ¹²³ Ho-Pham et al ²³ Koo et al ³⁷ Koo et al ³⁷	$\begin{array}{c} 69.26, df=6 (F\\ (P<0.0001) \\ \hline \\ 713.86, df=27\\ (P<0.0001) \\ \chi^2=1.92, df=2 \\ \hline \\ \\ \hline \\ \\ \hline \\$	P<0.0000 7 (P<0.00 2 (P=0.38 7 (P=0.38 7 (P=0.38 7 (P=0.38 7 (P=0.38 7 (P=0.38 7 (P=0.38 7 (P=0.38 7 (P=0.00 7 (P=0.00) 7 (P=0.00 7 (P=0.00) 7 (P=	001); <i>P</i> =91 0001); <i>P</i> = 8), <i>P</i> =0% C E 9 11 0 3 4 22 2	383 1% 3,599 :96% :ontrol :vents 1 1 1 4 1	Total 38 42 16 55 219 86 197	(% 4. 1. 5. 3. 5. 5.	3,063 (eight 6) 2 8 4 0 8 3 4	100 Odds M–H, r 0.94 (0 5.56 (2 27.92 (1.94 (0 2.72 (0 1.94 (0 2.72 (0 1.47 (0 6.65 (3	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 19 (50, 12.35) 22 (1.55, 501.86) 22 (1.55, 501.86) 22 (1.55, 501.86) 22 (1.52, 50	ar 85 00 02 10 10 12 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $t^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $t^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ²³ Wikinson et al ⁴³ Martineau et al ¹³³ HoPham et al ²² Koo et al ³⁷ Kim et al ³⁶ Chaudhary et al ³⁹⁰ Joshi et al ⁴⁶	F69.26, $df=6$ (F (P<0.0001) F713.86, $df=27$ (P<0.0001) $\chi^2=1.92$, $df=2$ TB Events 9 9 9 9 69 16 60 8 42 73 51 11	P<0.0000 P<0.0000 P<0.000 <pp>P<0.000 P<0.000</pp>	001); f ² =91 0001); f ² = 8), f ² =0% C E 9 1: 0 3 4 4 22 4: 0	383 % 3,599 96% control vents 1 1 4 1 9	Total 38 42 16 55 219 86 197 85 25	(% 4. 4. 5. 3. 5. 5. 5. 1.	3,063 reight 6) 2 8 4 0 8 3 4 1 4	100 Odds (M–H, r 0.94 (0 2.7.92 1.94 (0 2.7.2 (0 1.97 (1 40.45 (1.97 (1 40.45 (-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 19 5.0, 12.35) 22 1.55, 501.86) 22 1.55, 501.86) 22 1.55, 501.86) 22 1.55, 501.86) 22 1.52, 501.86) 22 1.52, 200 22 1.52, 200 22 1.52, 200 22 1.52, 200 22 2.22, 737.97) 22 2.27, 737.97 2.27, 737.97	ar 85 00 02 10 10 12 13 13 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or Subgroup Asian Grange et al ^{F3} Wilkinson et al ^{F3} Wilkinson et al ^{F3} Martineau et al ^{F3} Ho-Pham et al ^{F3} Ho-Pham et al ^{F3} Kim et al ^{F5} Kim et al ^{F5} Chaudhary et al ^{F9} Joshi et al ^{F6}	$\begin{array}{c} 69.26, df=6 \ (F\\ (P<0.0001) \end{array}$ $\begin{array}{c} 713.86, df=27\\ (P<0.0001) \end{array}$ $\begin{array}{c} \chi^2=1.92, df=2 \end{array}$ $\begin{array}{c} TB\\ Events \end{array}$ $\begin{array}{c} 9\\ 69\\ 16\\ 60\\ 8\\ 42\\ 73\\ 51\\ 11\\ 18\\ 83 \end{array}$	><0.0000 ? (P<0.000 ? (P<0.000 ? (P=0.38) Total 40 104 35 84 166 1165 70 25 94	01); <i>P</i> =91 0001); <i>P</i> = 8), <i>P</i> =0% C E 9 1 0 3 3 4 4 2 2 2 2	383 % 3,599 96% control vents 1 1 1 4 1 9 9 09	Total 38 42 16 55 219 86 197 85 25 25 282	(% 4. 4. 5. 3. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 leight (6) 2 8 4 0 8 3 4 1 1	Odds M–H, r 0.94 (0 5.56 (2 27.92 (1.94 (0 2.72 (2 6.65 (3 1.97 (1 40.45 (2.64 (1)	-13.05 (-19.02, -7.08) ratio Ye andom, 95% Cl 1.33, 2.68) 19 .50, 12.35) 20 1.55, 50.186) 20 .81, 9.20) 20 .81, 9.20) 20 .81, 9.20) 20 .81, 9.20) 20 .85, 11.49) 20 .00, 3.89) 20 .222, 737.97) 20 .33, 5.22) 20	ar 85 00 02 10 10 12 13 13 13 13 14	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ⁴³ Wilkinson et al ⁴⁵ Martineau et al ³³ Ho-Pham et al ³² Koo et al ³⁵ Kim et al ⁵⁵ Chaudhary et al ³⁶ Hong et al ⁴⁶ Joshi et al ⁴⁶ Hong et al ⁴⁶	F69.26, $df=6$ (F (P<0.0001) F713.86, $df=27$ (P<0.0001) $\chi^2=1.92$, $df=2$ TB Events 9 9 9 9 69 16 60 8 42 73 51 11	P<0.000 7 (P<0.00 2 (P=0.38 Total 40 104 35 84 166 116 165 70 25 94 60	001); f ² =91 0001); f ² = 8), f ² =0% C E 9 1: 0 3 4 4 22 4: 0	383 % 3,599 96% control vents 1 1 1 4 1 9 9 09	Total 38 42 16 55 55 219 86 197 85 25 252 252 2118	(% 4. 4. 1. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 (eight 6) 2 8 4 0 8 3 4 1 4 1 2 2	100 Odds M–H, r 0.94 (0 5.56 (2 27.92) 1.94 (0 6.65 (3 1.97 (0 6.65 (3 1.97 (1 40.45) 2.64 (1 1.22 (0	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 16 5.0, 12.35) 22 1.55, 501.36) 22 1.55, 501.36) 22 1.55, 501.36) 22 8.0, 2.68) 22 8.0, 2.68) 22 8.0, 2.68) 22 2.22, 737.97) 22 3.3, 5.22) 22 6.6, 2.28) 22	ar 85 00 02 10 10 12 13 13 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ²³ Wikinson et al ⁴ Sasidharan et al ²³ Martineau et al ²³ Martineau et al ²³ Ho-Pham et al ³² Kim et al ⁵⁵ Chaudhary et al ⁵⁶ Joshi et al ⁴⁶ Jubuils et al ⁴⁶ Jubuils et al ⁴⁷ Subtotal (95% CI) Total events	F69.26, $df=6$ (P (P <0.0001) (P <0.0001) $\chi^2=1.92$, $df=2$ TB Events 9 69 16 60 8 42 73 51 11 83 33 455	Correction of the second se	01); $r=91$ 0001); $r=$ 8), $r=0\%$ C E 9 1: 3 3 4 2 2 4 2 2 4 4 2 4 4 2 4 4 4 2 4 4 4 4 4 4 4 4 4 4 4 4 4	383 1% 3,599 96% control vents 1 1 1 4 1 9 9 9 9 9	Total 38 42 16 55 219 86 197 85 25 25 282	(% 4. 4. 1. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 leight (6) 2 8 4 0 8 3 4 1 1	100 Odds M–H, r 0.94 (0 5.56 (2 27.92) 1.94 (0 6.65 (3 1.97 (0 6.65 (3 1.97 (1 40.45) 2.64 (1 1.22 (0	-13.05 (-19.02, -7.08) ratio Ye andom, 95% Cl 1.33, 2.68) 19 .50, 12.35) 20 1.55, 50.186) 20 .81, 9.20) 20 .81, 9.20) 20 .81, 9.20) 20 .81, 9.20) 20 .85, 11.49) 20 .00, 3.89) 20 .222, 737.97) 20 .33, 5.22) 20	ar 85 00 02 10 10 12 13 13 13 13 14	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: . Study or subgroup Asian Grange et al ²³ Wilkinson et al ²³ Sasidharan et al ²³ Ho-Pham et al ²³ Ho-Pham et al ²³ Kin et al ⁵⁵ Chaudhary et al ³⁵ Jobbi et al ⁴⁷ Jubuis et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 ($\begin{array}{c} 69.26, df=6 (F\\ (P<0.0001) \\ \hline \\ 713.86, df=27\\ (P<0.0001) \\ \chi^2=1.92, df=2 \\ \hline \\ \textbf{TB} \\ \hline \\ \textbf{Events} \\ \hline \\ 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 8 \\ 33 \\ 33 \\ 455 \\ .04, df=10 (P=1) \\ \hline \\ \end{array}$	Correction of the second se	01); $r=91$ 0001); $r=$ 8), $r=0\%$ C E 9 1: 3 3 4 2 2 4 2 2 4 4 2 4 4 2 4 4 4 2 4 4 4 4 4 4 4 4 4 4 4 4 4	383 1% 3,599 96% control vents 1 1 1 4 1 9 9 9 9 9	Total 38 42 16 55 55 219 86 197 85 25 252 252 2118	(% 4. 4. 1. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 (eight 6) 2 8 4 0 8 3 4 1 4 1 2 2	100 Odds M–H, r 0.94 (0 5.56 (2 27.92) 1.94 (0 6.65 (3 1.97 (0 6.65 (3 1.97 (1 40.45) 2.64 (1 1.22 (0	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 16 5.0, 12.35) 22 1.55, 501.36) 22 1.55, 501.36) 22 1.55, 501.36) 22 8.0, 2.68) 22 8.0, 2.68) 22 8.0, 2.68) 22 2.22, 737.97) 22 3.3, 5.22) 22 6.6, 2.28) 22	ar 85 00 02 10 10 12 13 13 13 13 14	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ²³ Wikinson et al ⁴³ Martineau et al ²³ Martineau et al ²³ Ho-Pham et al ²⁴ Kim et al ⁸⁵ Chaudhary et al ⁸⁰ Jubuils et al ⁸⁶ Jubuils et al ⁸⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (African	$F_{0} = 6, df = 6 (F_{0} = 0, 0001)$ $F_{1} = 13.86, df = 27 (P < 0.0001)$ $\chi^{2} = 1.92, df = 2$ $F_{0} = 10, 0000$	Constant (Constant) Constant) Constant) 40 104 104 104 105 84 106 116 107 25 94 60 959 959	01); <i>P</i> =91 0001); <i>P</i> = B), <i>P</i> =0% C C C C C C C C C C	383 % 3,599 96% control vents 1 1 1 4 1 9 9 9 9	Total 38 42 16 55 219 97 85 25 25 282 118 1,163	(9 4. 4. 5. 3. 5. 5. 5. 5. 5. 5. 4	3,063 (eight 6) 2 8 4 0 8 3 4 1 4 1 2 2 3.7	100 Odds M-H, r 0.94 (0 5.56 (2 27.92 1.94 (0 2.72 (0 1.97 (0 1.47 (0 1.97 (1 1.97 (1 1.92 (1	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 	ar 85 00 02 10 10 12 13 13 13 13 14 14	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $t^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Heterogeneity: $t^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ²³ Wilkinson et al ²⁵ Martineau et al ²³ Martineau et al ²³ Martineau et al ²³ Martineau et al ²⁴ Martineau et al ²⁵ Chaudhary et al ²⁶ Chaudhary et al ²⁶ Multine et al ²⁷ Subtotal (95% CI) Total events Heterogeneity: $t^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (African Wejse et al ⁵	$\begin{array}{c} 69.26, df=6 (F\\ (P<0.0001) \\ \hline \\ 713.86, df=27\\ (P<0.0001) \\ \chi^2=1.92, df=2 \\ \hline \\ \textbf{TB} \\ \hline \\ \textbf{Events} \\ \hline \\ 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 8 \\ 33 \\ 33 \\ 455 \\ .04, df=10 (P=1) \\ \hline \\ \end{array}$	Control (Control (Contro) (Contro) (Contro) (Contro) (Contro) (Contro) (Contro) (01); $r=91$ 0001); $r=$ 8), $r=0\%$ C E 9 1: 3 3 4 2 2 4 2 2 4 4 2 4 4 2 4 4 4 2 4 4 4 4 4 4 4 4 4 4 4 4 4	383 % 3,599 996% control 2009 11 12 17 5	Total 38 42 16 55 55 219 86 197 85 25 252 252 252 2118	(% 4. 4. 1. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 (eight 6) 2 2 8 4 4 1 1 1 2 3.7 6	100 Odds M-H, r 0.94 (0 5.56 (2 27.92 1.94 (0 2.72 (0 1.97 (0 1.47 (0 2.62 (1 1.22 (0 2.62 (1	-13.05 (-19.02, -7.08) ratio Y (andom, 95% Cl 	ar 85 00 02 10 12 13 13 13 13 14 14 14	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $t^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $t^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ²³ Wilkinson et al ²³ Martineau et al ²³ Ho-Pham et al ²⁶ Chaudhary et al ²⁹ Lossi et al ²⁷ Martineau et al ²³ Chaudhary et al ²⁹ Jubuis et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: $t^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (Atrican Wejse et al ² Gibney et al ²	$\begin{array}{c} 69.26, df=6 \ (P<0.0001) \\ (P<0.0001) \\ \chi^{2}=1.92, df=2 \\ \hline \\ \textbf{Events} \\ 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ 455 \\ .04, df=10 \ (P=(P<0.0001) \\ 31 \\ 31 \\ 6 \end{array}$	P (P<0.000) P (P<0.00 Total 40 40 40 104 35 84 165 165 70 95 95 9500017 362 40 50	01); <i>P</i> =91 0001); <i>P</i> = <u>P</u> 9 1: 3 3 4 4 2: 2: 2: 5; 5; 5; 5; 5; 5; 5; 5; 5; 5;	383 % 3,599 906% control 1 1 1 4 1 9 9 9 17	Total 38 42 16 55 219 86 197 85 282 2818 1,163 494 115 50	(9 4. 4. 1. 5. 5. 5. 5. 5. 5. 4. 4. 3.	3,063 reight 6 2 8 4 1 1 2 8 3 4 1 1 2 8 3 4 1 1 2 8 3 4 1 1 2 8 3 4 1 1 1 2 8 3 4 1 1 1 1 1 1 1 1	100 Odds (M-H, r 0.94 (0 5.56 (2 27.92 (1.94 (0 2.72 (2 1.97 (1 40.45 (2.64 (1 1.22 (0 2.62 (1 0.62 (0 10.21 (1.23 (1.23 (-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 16 .50, 12.35) 22 .155, 501.86) 22 .155, 501.86) 22 .155, 501.86) 22 .80, 2.68) 22 .80, 2.68) 22 .80, 2.68) 22 .80, 2.68) 22 .85, 11.49) 22 .00, 3.89) 22 .22, 737.97) 22 .33, 5.22) 22 .63, 4.23) .39, 0.97) 20 .35, 4.32) 22	ar 85 000 002 10 11 13 13 13 13 14 14 14 14 14	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or Subgroup Asian Grange et al ⁴³ Wilkinson et al ⁴³ Martineau et al ³³ Ho-Pham et al ²⁴ Martineau et al ³⁴ Hong et al ⁴⁶ Jubuis et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (African Weige et al ⁵ Gibney et al ⁴⁶ Martineau et al ⁴⁵	$\begin{array}{c} \textbf{c} \textbf{c} \textbf{c} \textbf{c} \textbf{c} \textbf{c} \textbf{c} \textbf$	P<0.0000 (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0.0,0) (P<0	01); P=91 0001); P= C E C E C E C E C E C E C E C E C C C E C C C C	383 % 3,599 996% control vents 1 1 1 4 1 9 99 9 17 5 9 7	Total 38 42 16 55 219 86 197 85 282 118 1,163 494 115 50 778	(9 4. 4. 1. 5. 3. 5. 5. 5. 4. 4. 3. 5. 5. 4. 3. 5. 5. 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 reight 6 2 2 8 4 4 1 2 2 8 3 4 4 1 2 2 8 7 6 7 7 6 6	100 Odds M-H, r 0.94 (0 5.56 (2 27.92 (1.94 (0 2.47 (0 2.47 (0 2.62 (1 1.22 (0 2.62 (1 0.62 (0 1.0.21 (1.23 (0 5.49 (3	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 1.33, 2.68) 19 5.0, 12.35) 20 1.55, 501.86) 20 1.55, 501.86) 20 25, 3.95) 20 26, 3.95) 20 27, 37, 97) 20 28, 51, 14.9) 20 20, 3.89) 20 22, 27, 37, 97) 20 33, 5.22) 20 1.65, 2.28) 20 1.65, 2.28, 20 1.65, 2.58,	ar 85 00 02 10 12 13 13 13 13 13 14 14 14 14 14	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴⁵ Sasidharan et al ²⁸ Martineau et al ³⁹ Hor-Pham et al ³⁹ Hor Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (Atrican Wejse et al ² Gibney et al ²⁶ Subenoti (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (Atrican Wejse et al ²⁶ Sidenhoff et al ¹¹⁶	$\begin{array}{c} 69.26, df=6 \ (P<0.0001) \\ (P<0.0001) \\ \chi^2=1.92, df=2 \\ \hline \\ \textbf{Events} \\ 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ 455 \\ .04, df=10 \ (P=(P<0.0001) \\ 131 \\ 6 \\ 155 \\ 15 \\ 15 \\ \end{array}$	r (P<0.000 r (P<0.00 t (P=0.34 40 104 35 84 166 116 165 70 94 60 959 95 99 95 95 95 91 95 92 91 95 95 92 92 95 95 95 95 95 95 95 95 95 95 95 95 95	01); P=91 0001); P=91 0001); P= C C C C C C C C C C C C C C C C C C C	383 % 3,599 996% tontrol 1 1 1 4 1 9 9 9 17 5 9 7 5	Total 38 42 16 55 25 28 28 197 85 28 28 2118 1,163 494 4115 50 778 9	(9 4. 4. 1. 5. 5. 5. 5. 5. 44 5. 4. 3. 3. 5.	3,063 reight (a) 2 2 8 4 4 0 8 3 4 1 1 2 5.7 6 7 7 6 1 1	Odds M–H, r 0.94 (0 5.56 (2 2.792) 1.94 (0 2.72 (0 1.47 (0 6.65 (3 1.97 (1 40.45) 2.64 (1 1.22 (0 2.62 (1 0.62 (0 10.21 (1 1.23 (0 5.49 (3 1.23 (0 5.49 (3 1.20 (0 5.49 (1 5.49 (1 5	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 19 5.0, 12.35) 20 1.55, 501.86) 20 1.55, 3.95) 20 1.55, 4.23) 3.5, 4.32) 20 1.55, 4.32) 20 2.55, 4.35, 4.	ar 85 000 002 10 10 12 13 13 13 13 14 14 14 14 14 11 11 11 11 2	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ⁴³ Wilkinson et al ⁴³ Marineau et al ⁴³ Marineau et al ⁴³ Ho-Pham et al ²⁴ Kim et al ⁴⁵ Ho-Pham et al ⁴² Kim et al ⁴⁵ Doshi et al ⁴⁶ Jubuits et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (African Weise et al ⁵ Gibhey et al ¹⁴ Martineau et al ⁴³ Steenhoff et al ¹⁴	$\begin{array}{c} \textbf{c69.26, df=6 (F}\\ (P<0.0001) \\ \textbf{c713.86, df=27}\\ (P<0.0001) \\ \chi^2=1.92, df=2 \\ \textbf{TB} \\ \textbf{Events} \\ \textbf{F} \\ \textbf{Events} \\ \textbf{73} \\ \textbf{60} \\ \textbf{82} \\ \textbf{73} \\ \textbf{51} \\ \textbf{61} \\ \textbf{83} \\ \textbf{33} \\ \textbf{455} \\ \textbf{504, df=10 (P=(P<0.0001))} \\ \textbf{31} \\ \textbf{61} \\ \textbf{65} \\ \textbf{51} $	Constant Sector 2018 (Constant Sector 2018) (Constant Sector 2018	01); <i>P</i> =91 0001); <i>P</i> =9 0001); <i>P</i> = C C C C C C C C C C	383 % 3,599 996% control vents 1 1 1 1 4 1 9 9 9 9 17 5 5 7 5	Total 38 42 16 55 219 86 197 85 282 282 118 1,163 494 115 50 178 19 43	(9 4. 4. 5. 5. 5. 5. 5. 5. 4. 4. 3. 5. 4. 4. 4. 4. 4. 4. 4. 5. 5. 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 leight 6) 2 8 4 1 1 2 8 3 4 1 1 2 5,7 6 7 7 6 1 2 2	100 Odds M-H, r 0.94 (0 5.56 (2 27.92 (1.94 (0 2.72 (0 2.72 (0 1.94 (0 2.47 (0 2.62 (1 0.62 (0 1.22 (1 0.62 (0 1.23 (0 5.49 (3 1.24 (0 1.24 (0 5.49 (3 1.24 (0 1.24 (-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 1.33, 2.68) 19 5.0, 12.35) 20 1.55, 501.86) 20 1.55, 501.86) 20 1.55, 501.86) 20 2.53, 55) 20 2.63, 2.63) 20 2.22, 737.97) 20 3.3, 5.22) 20 (.66, 2.28) 20 (.66, 2.28) 20 (.66, 2.28) 20 (.66, 2.28) 20 (.66, 2.28) 20 (.63, 4.23) 20 (.35, 4.32) 20 (.35, 4.	ar 85 00 02 10 12 13 13 13 13 14 14 14 14 14 14 14 11 11 11 12 12	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: . Study or subgroup Asian Grange et al ²³ Wilkinson et al ⁴³ Martineau et al ³³ Martineau et al ³³ Ho-Pham et al ²³ Kim et al ³⁶ Chaudhary et al ³⁹ Jubuis et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Gibney et al ⁵ Gibney et al ⁵ Gibney et al ⁵ Siteenhoff et al ¹⁴ Martineau et al ⁵³ Steenhoff et al ¹⁴⁵ Steenhoff et al ¹⁴⁵ Asia et al ⁴³⁵	$\begin{array}{c} 69.26, df=6 \ (P<0.0001) \\ (P<0.0001) \\ \chi^2=1.92, df=2 \\ \hline \\ \textbf{Events} \\ 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 42 \\ 73 \\ 51 \\ 11 \\ 83 \\ 33 \\ 455 \\ .04, df=10 \ (P=(P<0.0001) \\ 131 \\ 6 \\ 155 \\ 15 \\ 15 \\ \end{array}$	r (P<0.000) r (P<0.01) r (P=0.31) r (P=0.31) r (P=0.31) r (P=0.31) r (P=0.31) r (P=0.31) r (P=0.31) r (P=0.01) r (P=0.01)	01); <i>P</i> =91 0001); <i>P</i> =9 0001); <i>P</i> =0% C E E E C C C C C C C C C C	383 % 3,599 996% toutrol vents 1 1 1 4 1 9 9 9 9 17 5 5 9 7 5 5 6	Total 38 42 16 55 219 86 197 85 25 282 118 1,163 494 115 50 178 19 43 157 347	(9 4.4 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 44 4. 3. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 eight 6) 2 8 4 4 1 1 2 8 3 4 4 1 2 5.7 7 6 7 7 6 7 7 6 1 2 4 2 2 4 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4	100 Odds (M-H, r 0.94 (0) 5.56 (2) 27.92 (1.94 (0) 2.72 (0) 1.47 (0) 6.65 (3) 2.64 (1) 1.23 (0) 2.62 (1) 0.62 (0) 1.24 (0) 5.49 (3) 1.00 (0) 1.24 (0) 5.49 (3) 1.00 (0) 1.44 (0) 5.49 (3) 1.00 (0) 1.44 (0) 3.68 (2) 0.58 (0) 0.58 (0)	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 1.33, 2.68) 19 .50, 12.35) 20 .55, 3.95) 20 .55, 3.95) 20 .61, 22, 35) 20 .63, 2.22, 737.97) 20 .33, 5.22) 20 .66, 2.28) 20 .66, 2.28) 20 .66, 2.28) 20 .63, 4.23) 20 .53, 5.22 20 .64, 2.28) 20 .64, 2.28) 20 .65, 2.28) 20 .63, 4.23) 20 .64, 5, 8.75) 20 .21, 4.76) 20 .50, 4.14) 20 .18, 6.22) 20 .14, 102 .22, 27, 31, 102 .23, 102 .24, 25, 23, 97) 20 .25, 4.14) 20 .26, 4.14) 20 .26, 4.14) 20 .26, 26, 22 .26, 24, 25 .27,	ar 85 000 002 10 10 12 13 13 13 13 14 14 14 14 14 11 11 11 11 2	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: . Study or subgroup Asian Grange et al ²³ Wilkinson et al ²³ Martineau et al ³³ Martineau et al ³³ Hong et al ²⁹ Jubulis et al ⁴⁹ Jubulis et al ⁴⁹ Jubulis et al ⁴⁹ Jubulis et al ⁴⁹ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Gioney et al ⁵ Gioney et al ⁵ Gioney et al ⁵ Steenhoff et al ¹⁴ Narsineau et al ⁵³ Steenhoff et al ¹⁴⁵ Steenhoff et al ¹⁴⁵ Martineau et al ⁵⁵ Steenhoff et al ¹⁴⁵		Constant Sector 2018 (Constant Sector 2018) (Constant Sector 2018	01); <i>P</i> =91 0001); <i>P</i> =9 0001); <i>P</i> =0% C E E E C C C C C C C C C C	383 % 3,599 996% toutrol vents 1 1 1 4 1 9 9 9 9 17 5 5 9 7 5 5 6	Total 38 42 16 55 219 86 197 85 25 282 118 1,163 494 4115 50 778 19 43 157	(9 4.4 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 44 4. 3. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 reight (a) 2 2 8 4 0 8 3 4 1 1 2 2 5.7 6 6 7 7 7 7 6 6 1 2 4 4 1 2 2 3 4 4 1 1 2 2 3 4 4 1 1 2 2 3 4 4 1 1 2 2 3 3 4 4 1 1 1 1 1 1 1 1 1 1 1 1 1	100 Odds (M-H, r 0.94 (0) 5.56 (2) 27.92 (1.94 (0) 2.72 (0) 1.47 (0) 6.65 (3) 2.64 (1) 1.23 (0) 2.62 (1) 0.62 (0) 1.24 (0) 5.49 (3) 1.00 (0) 1.24 (0) 5.49 (3) 1.00 (0) 1.44 (0) 5.49 (3) 1.00 (0) 1.44 (0) 3.68 (2) 0.58 (0) 0.58 (0)	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 16 5.0, 12.35) 22 1.55, 501.36) 22 1.55, 501.36) 22 8.0, 2.68) 22 1.55, 501.36) 22 2.0, 3.3, 522) 22 (.63, 4.23) 22 3.3, 5.29) 22 (.33, 5.22) 22 (.33, 4.23) 22 (.35, 4.32) 22 (.35, 4.32) 22 (.35, 4.32) 22 (.36, 4.14) 22 (.36, 2.22) 22 (.37, 4.14) 22 (.36, 2.22) 22 (.37, 4.14) 22 (.38, 6.22) 22 (.38, 4.22) 22 (.39, 0.97) 22 (.3	ar 85 000 002 10 10 12 13 13 13 13 14 14 14 007 008 111 111 112 122 12 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ⁴³ Wilkinson et al ⁴³ Milkinson et al ⁴³ Marineau et al ⁴³ Ho-Pham et al ²⁴ Asiandharan et al ²⁴ Hoad the al ⁴⁵ Hoad the al ⁴⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Steenhoff et al ¹⁴ Marineau et al ⁴⁵ Steenhoff et al ⁴⁴ Steenhoff et al ⁴⁵ Steenhoff et al ⁴⁵ Stebtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=80$	$\begin{array}{c} \text{Fe}(P < 0, odd) \\ \text{Fe}(P < 0, odd) \\$	Constant Sector 2018 (Constant Sector 2018) (Constant Sector 2018	01); <i>P</i> =91 0001); <i>P</i> = C C C C C C C C	383 % 3,599 996% control vents 1 1 4 1 9 9 9 7 5 9 7 5 6 5 337	Total 38 42 16 55 219 86 197 85 25 282 118 1,163 494 115 50 178 19 43 157 347	(9 4.4 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 44 4. 3. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 eight 6) 2 8 4 4 1 1 2 8 3 4 4 1 2 5.7 7 6 7 7 6 7 7 6 1 2 4 2 2 4 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4	100 Odds (M-H, r 0.94 (0) 5.56 (2) 27.92 (1.94 (0) 2.72 (0) 1.47 (0) 6.65 (3) 2.64 (1) 1.23 (0) 2.62 (1) 0.62 (0) 1.24 (0) 5.49 (3) 1.00 (0) 1.24 (0) 5.49 (3) 1.00 (0) 1.44 (0) 5.49 (3) 1.00 (0) 1.44 (0) 3.68 (2) 0.58 (0) 0.58 (0)	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 1.33, 2.68) 19 .50, 12.35) 20 .55, 3.95) 20 .55, 3.95) 20 .61, 22, 35) 20 .63, 2.22, 737.97) 20 .33, 5.22) 20 .66, 2.28) 20 .66, 2.28) 20 .66, 2.28) 20 .63, 4.23) 20 .53, 5.22 20 .64, 2.28) 20 .64, 2.28) 20 .65, 2.28) 20 .63, 4.23) 20 .64, 5, 8.75) 20 .21, 4.76) 20 .50, 4.14) 20 .18, 6.22) 20 .14, 102 .22, 27, 31, 102 .23, 102 .24, 25, 23, 97) 20 .25, 4.14) 20 .26, 4.14) 20 .26, 4.14) 20 .26, 26, 22 .26, 24, 25 .27,	ar 85 000 002 10 10 12 13 13 13 13 14 14 14 007 008 111 111 112 122 12 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ⁴³ Martineau et al ⁴³³ Ho-Pham et al ⁴²³ Martineau et al ⁴³³ Ho-Pham et al ⁴²³ Kim et al ⁴⁵⁵ Chaudhary et al ⁴⁵⁰ Jubuils et al ⁴⁶⁵ Jubuils et al ⁴⁶⁵ Jubuils et al ⁴⁶⁵ Jubuils et al ⁴⁶⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (African Weijse et al ⁴⁶⁵ Steenhoff et al ¹¹⁴⁵ Conesa-Botella et al ^{12,51} Mastala et al ⁴⁵⁵ Steenhoff et al ¹¹⁵ Conesa-Botella et al ^{12,51} Mastala et al ⁴⁵⁵ Steenhoff et al ¹¹⁵ Conesa-Botella et al ^{12,51} Mastala et al ⁴⁵⁵ Steenhoff et al ¹¹⁵ Conesa-Botella et al ^{12,51} Mastala et al ⁴⁵⁵ CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=80$	$\begin{array}{c} \text{Fe}(P < 0, odd) \\ \text{Fe}(P < 0, odd) \\$	Constant Sector 2018 (Constant Sector 2018) (Constant Sector 2018	01); <i>P</i> =91 0001); <i>P</i> = C C C C C C C C	383 % 3,599 996% control vents 1 1 4 1 9 9 9 7 5 9 7 5 6 5 337	Total 38 42 16 55 219 86 197 85 25 282 118 1,163 494 115 50 178 19 43 157 347	(9 4.4 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 44 4. 3. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 eight 6) 2 8 4 4 1 1 2 8 3 4 4 1 2 5.7 7 6 7 7 6 7 7 6 1 2 4 2 2 4 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4	100 Odds (M-H, r 0.94 (0) 5.56 (2) 27.92 (1.94 (0) 2.72 (0) 1.47 (0) 6.65 (3) 2.64 (1) 1.23 (0) 2.62 (1) 0.62 (0) 1.24 (0) 5.49 (3) 1.00 (0) 1.24 (0) 5.49 (3) 1.00 (0) 1.44 (0) 5.49 (3) 1.00 (0) 1.44 (0) 3.68 (2) 0.58 (0) 0.58 (0)	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 1.33, 2.68) 19 .50, 12.35) 20 .55, 3.95) 20 .55, 3.95) 20 .61, 22, 35) 20 .63, 2.22, 737.97) 20 .33, 5.22) 20 .66, 2.28) 20 .66, 2.28) 20 .66, 2.28) 20 .63, 4.23) 20 .53, 5.22 20 .64, 2.28) 20 .64, 2.28) 20 .65, 2.28) 20 .63, 4.23) 20 .64, 5, 8.75) 20 .21, 4.76) 20 .50, 4.14) 20 .18, 6.22) 20 .14, 102 .22, 27, 31, 102 .23, 102 .24, 25, 23, 97) 20 .25, 4.14) 20 .26, 4.14) 20 .26, 4.14) 20 .26, 26, 22 .26, 24, 25 .27,	ar 85 000 002 10 10 12 13 13 13 13 14 14 14 007 008 111 111 112 122 12 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: . Study or subgroup Asian Grange et al ²³ Wilkinson et al ²³ Sasidharan et al ²³ Martineau et al ³³ Ho-Phan et al ²³ Kin et al ⁵³ Chaudhary et al ³⁰ Jubuis et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (Arrican Martineau et al ¹⁵⁵ Steenhoff et al ¹¹⁶ Steenhoff et al ¹¹⁶ Steenhoff et al ¹¹⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Total events Heterogeneity: $r^2=0.50$ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.50$ Test for overall effect: Z=1.50 (Total events Heterogeneity: $r^2=1.23$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified	$\begin{array}{c} 69.26, df=6 \ (F\\ (P<0.0001) \end{array} \\ \hline (P<0.0001) \end{array} \\ \hline (P<0.0001) \\ \chi^2=1.92, df=2 \\ \hline \mathbf{TB} \\ \mathbf{Events} \\ \hline 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 455 \\ 51 \\ 11 \\ 11 \\ 83 \\ 33 \\ 455 \\ 504, df=10 \ (P=0) \\ (P<0.0001) \end{array} \\ \hline \begin{array}{c} 31 \\ 31 \\ 6 \\ 155 \\ 15 \\ 15 \\ 15 \\ 15 \\ 15 \\ 1$	Constant Sector 2018 (Constant Sector 2018) (Constant Sector 2018	01); <i>P</i> =91 0001); <i>P</i> = C C C C C C C C	383 % 3,599 996% outrol vents 1 1 1 4 1 9 9 9 7 5 9 7 5 6 5 37	Total 38 42 55 219 85 25 282 118 1,163 494 115 50 178 19 43 157 347 1,403	(*) 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 eight 6) 2 8 4 4 1 2 8 4 1 1 2 8 3 4 1 1 2 8 3 4 1 1 2 8 3 4 1 1 2 8 3 4 1 1 2 8 3 4 5 7 6 6 7 7 6 7 7 6 7 7 6 7 7 7 6 7 7 7 7 7 7 7 7 7 7 7 7 7	100 Odds (M-H, r 0.94 (0 5.56 (2 27.92 (1.94 (0 2.72 (0 1.47 (0 6.65 (3 1.97 (1 1.22 (0 2.62 (1 0.62 (0 10.21 (1.23 (0 5.49 (3 1.02 (0 1.02 (0 1.44 (0 3.68 (0 1.89 (0	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 16 5.0, 12.35) 22 1.55, 501.86) 22 1.55, 501.86) 22 1.55, 501.86) 22 1.50, 22, 23 8.5, 11.49) 22 2.0, 3.89) 22 2.22, 737.97) 22 3.3, 5.22) 22 (.66, 2.28) 22 (.63, 4.23) 1.39, 0.97) 20 (.35, 4.32) 22 (.35, 4.32) 22 (.35, 4.32) 22 (.31, 1.06) 22 (.32, 4.33)	ar 85 00 002 10 110 12 13 13 13 13 14 14 14 14 14 11 11 12 12 13 13 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or Subgroup Asian Grange et al ⁴³ Wilkinson et al ⁴³ Martineau et al ⁴³ Ho-Pham et al ⁴² Kim et al ⁹⁵ Chaudhary et al ¹²⁹ Jubuis et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (African Weijse et al ⁹⁵ Subtotal et al ¹⁴⁵ Martineau et al ⁵⁵ Steenhoff et al ¹⁴⁵ Martineau et al ⁵⁵ Steenhoff et al ¹⁴⁵ Martineau et al ⁵⁵ Steenhoff et al ¹⁴⁵ Martineau et al ⁵⁵ Steonhoff et al ¹⁴⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sita-Lumsden et al ⁵⁰	$\begin{array}{c} \text{Fe}(P < 0, off = 6 \ (F < 0, cool) \\ (F < 0, oool) \\ \text{F13.86, } df = 27 \\ (P < 0, oool) \\ \chi^2 = 1.92, \; df = 2 \\ \hline \\ \textbf{FB} \\ \textbf{Events} \\ \hline \\ \textbf{9} \\ \textbf{60} \\ \textbf{8} \\ 422 \\ \textbf{73} \\ \textbf{51} \\ \textbf{11} \\ \textbf{83} \\ \textbf{33} \\ \textbf{455} \\ \textbf{.04, } df = 10 \ (P = (P < 0, oool)) \\ \textbf{31} \\ \textbf{31} \\ \textbf{6} \\ \textbf{155} \\ \textbf{15} \\ \textbf{19} \\ \textbf{68} \\ \textbf{31} \\ \textbf{31} \\ \textbf{65} \\ \textbf{15} \\ \textbf{19} \\ \textbf{68} \\ \textbf{31} \\ \textbf{356} \\ \textbf{.11, } df = 7 \ (P < 0 \\ (P = 0.13)) \\ \textbf{167} \end{array}$	Constant Sector 2018 (Constant Sector 2018) (Constant Sector 2018	01); <i>P</i> =91 0001); <i>P</i> = C C C C C C C C C C	383 % 3,599 996% control vents 1 1 1 4 1 9 009 9 17 5 9 7 5 6 5 37	Total 38 42 16 55 219 86 197 85 25 282 118 1,163 494 115 50 178 19 494 115 57 177 1,403	(*) 4. 4. 4. 1. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 reight 6 2 2 8 4 4 1 2 8 3 4 4 1 2 8 3 4 4 1 2 8 3 4 4 1 2 6 7 7 6 6 7 7 6 6 1 2 2 8 4 4 0 8 8 3 3 4 4 1 1 2 2 8 8 4 4 1 1 2 2 8 4 4 1 1 1 2 2 3 3 4 4 1 1 1 2 2 3 3 4 4 1 1 1 2 2 3 3 4 4 1 1 1 1 1 1 1 1 1 1 1 1 1	100 Odds M-H, r 0.94 (0 5.56 (2 27.92 (1 9.47 (0 1.47 (0 2.62 (1 1.97 (0 1.47 (0 1.42 (0 5.49 (3 1.92 (0 1.23 (0 5.49 (3 1.94 (0 1.48 (0 1.89 (0 1.89 (0 1.89 (0 1.89 (0	-13.05 (-19.02, -7.08) ratio Y (andom, 95% CI 	ar 85 000 010 110 121 133 133 14 14 07 08 111 112 122 123 13 13 14 14 07 08 111 122 13 13 13 14 14 00 00 00 00 00 00 00 00 00 0	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: r^2 =129.43; χ^2 =1 Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: r^2 =235.82; χ^2 =1 Test for overall effect: Z=4.28 (Test for subgroup differences: . Study or subgroup Asian Grange et al ²³ Wilkinson et al ²³ Martineau et al ²³ Martineau et al ²³ Martineau et al ²³ Martineau et al ²³ Kine et al ²⁵ Chaudhary et al ²⁹ Jubuis et al ⁴⁷ Subtotal (95% CI) Total events Heterogeneity: r^2 =0.41; χ^2 =35 Test for overall effect: Z=1.50 (African Martineau et al ³⁵ Steenhoff et al ¹¹ Conesa-Botella et al ¹²⁶ Subtotal (95% CI) Total events Heterogeneity: r^2 =1.23; χ^2 =80 Test for overall effect: Z=1.50 (Stehtorig et al ⁴⁶ Subtotal (95% CI) Total events Heterogeneity: r^2 =1.23; χ^2 =80 Test for overall effect: Z=1.50 (Stehtorig et al ⁴⁶ Sital-Lumsden et al ⁴⁶	$\begin{array}{c} 69.26, df=6 \ (F\\ (P<0.0001) \end{array} \\ \hline (P<0.0001) \end{array} \\ \hline (P<0.0001) \\ \chi^2=1.92, df=2 \\ \hline \mathbf{TB} \\ \mathbf{Events} \\ \hline 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 455 \\ 51 \\ 11 \\ 11 \\ 83 \\ 33 \\ 455 \\ 504, df=10 \ (P=0) \\ (P<0.0001) \end{array} \\ \hline \begin{array}{c} 31 \\ 31 \\ 6 \\ 155 \\ 15 \\ 15 \\ 15 \\ 15 \\ 15 \\ 1$	Constant Sector 2015 (Constant Sector 2015) (Constant Sector 2015	01); <i>P</i> =91 0001); <i>P</i> = C C C C C C C C	383 % 3,599 996% control vents 1 1 1 4 1 9 9 9 7 5 9 7 5 6 5 37 3	Total 38 42 16 16 55 219 85 25 282 118 1,163 494 115 50 178 19 43 157 347 1,403 130 72	(*) 4. 4. 1. 1. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 4. 4. 4. 4. 4. 4. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 (eight 6) 2 2 8 4 4 1 2 8 4 1 1 2 8 4 1 1 2 8 7 7 6 7 7 6 1 2 2 7 7 6 1 2 2 8 4 4 0 8 3 4 4 1 2 2 8 7 7 6 9 7 7 7 6 9 7 7 7 7 7 7 7 7 7 7 7 7 7	100 Odds (M-H, r 0.94 (0 5.56 (2 27.92 (1.94 (0 2.72 (2) 1.97 (1 40.45 (2.64 (1 1.22 (0 2.62 (1 0.62 (0 10.21 (1.23 (0 1.23 (0 1.2	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.33, 2.68) 19 5.05, 12.35) 20 1.55, 501.86) 20 1.55, 501.86) 20 1.55, 501.86) 20 1.52, 501.86 2.52, 12 2.53, 4.23) 1.39, 0.97) 20 1.35, 4.32) 20 1.35, 4.32) 20 1.35, 4.32) 20 1.35, 4.32) 20 1.35, 4.32) 20 1.31, 1.08) 20 1.32, 4.33)	ar 85 00 002 10 12 13 13 13 14 14 14 14 10 07 08 11 11 12 12 13 13 13 13 13 13 13 13 13 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.00 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ⁴³ Martineau et al ⁴³³ Ho-Pham et al ⁴²⁸ Martineau et al ⁴³³ Ho-Pham et al ⁴²⁹ Martineau et al ⁴³³ Ho-Pham et al ⁴²⁹ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (African Weijse et al ⁴⁶ Steenhoff et al ⁴¹⁵ Stehoff et al ⁴⁴⁵ Stehoff et al ⁴⁵⁵ Stehoff et al ⁴⁶⁵ Stehoff et al ⁴⁷⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sita-Lumsden et al ⁴⁶⁰ Nielsen et al ⁴⁶⁵	$\begin{array}{c} \text{F69.26, } df = 6 \ (F(P < 0.0001) \\ \text{F713.86, } df = 27 \\ (P < 0.0001) \\ \chi^2 = 1.92, \\ df = 27 \\ \chi^2 = 1.92, \\ \chi^2 = 1$	Constant Sector 2015 (Constant Sector 2015) (Constant Sector 2015	01); <i>P</i> =91 0001); <i>P</i> = C C C C C C C C C C	383 % 3,599 996% control vents 1 1 1 1 4 1 9 9 9 9 17 5 9 7 5 6 5 3 7 7 5 6 5 3 3 2	Total 38 42 16 16 55 219 85 25 282 118 1,163 494 115 50 178 19 43 157 347 1,403 130 72 235	(*) 4.4 4.1 1.1 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 4 4 4 4	3,063 Feight 6) 2 2 8 4 4 0 8 3 4 1 2 8 4 1 2 8 7 7 6 7 7 6 1 2 2 8 7 7 6 1 2 2 8 7 7 6 1 2 8 7 7 6 9 7 7 7 6 9 7 7 7 7 6 9 7 7 7 7 7 7 7 7 7 7 7 7 7	100 Odds M-H, r 0.94 (0 5.56 (2 2.7.92 (2 1.94 (0 2.47 (0 1.97 (0 1.97 (0 1.97 (1 1.22 (0 2.62 (1 0.62 (0 1.92 (1 1.23 (0 5.49 (3 1.94 (0 1.44 (0 1.89 (0	-13.05 (-19.02, -7.08) ratio Y (random, 95% Cl 	ar 85 00 02 10 12 13 13 13 14 14 14 14 14 14 11 12 13 13 13 13 13 13 13 13 13 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ²³ Wilkinson et al ²³ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (Arican Martineau et al ³⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (Arican Martineau et al ³⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (Arican Martineau et al ³⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sital-Lumsden et al ³⁶ Sital events Heterogeneity: $r^2=1.23$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sital-Lumsden et al ³⁶ Sital events Heterogeneity: $r^2=1.43$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sital-Lumsden et al ³⁶ Sital events Heterogeneity: $r^2=1.43$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sital-Lumsden et al ³⁶ Sital events Heterogeneity: $r^2=1.43$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sital-Lumsden et al ³⁶ Sital events Heterogeneity: $r^2=1.43$; $\chi^2=80$ Test for overall effect: Z=1.50 (Sital events Heterogeneity: $r^2=1.43$; $\chi^2=80$ Test for overall effect: Z=1.50 (Sital events Heterogeneity: $r^2=1.43$; $\chi^2=80$ Test for overall effect: Z=1.50 (Sital events Heterogeneity: $r^2=1.43$; $\chi^2=80$ Test for overall effect: Z=1.50 (Sital events Heterogeneity: $r^2=1.43$; $\chi^2=80$ Test for overall effect: Z=1.50 (Sital events Sital events Sit	$\begin{array}{c} 69.26, df=6 \ (F\\ (P<0.0001) \end{array} \\ \hline (P<0.0001) \end{array} \\ \hline (P<0.0001) \\ \chi^2=1.92, df=2 \\ \hline \mathbf{TB} \\ \mathbf{Events} \\ \hline 9 \\ 69 \\ 16 \\ 60 \\ 8 \\ 455 \\ 51 \\ 11 \\ 11 \\ 83 \\ 33 \\ 455 \\ 504, df=10 \ (P=0) \\ (P<0.0001) \end{array} \\ \hline \begin{array}{c} 31 \\ 31 \\ 6 \\ 155 \\ 15 \\ 15 \\ 15 \\ 15 \\ 15 \\ 1$	Constant Sector 2015 (Constant Sector 2015) (Constant Sector 2015	01); <i>P</i> =91 0001); <i>P</i> = C C C C C C C C	383 % 3,599 996% control vents 1 1 1 1 4 1 9 9 9 9 17 5 9 7 5 6 5 3 7 7 5 6 5 3 3 2	Total 38 42 16 16 55 219 85 25 282 118 1,163 494 115 50 178 19 43 157 347 1,403 130 72	(*) 4.4 4.1 1.1 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 4 4 4 4	3,063 reight 6 2 2 4 4 4 1 2 2 8 3 4 4 1 2 2 7 6 7 7 6 7 7 6 1 2 4 2 2 7 7 7 6 1 2 2 7 7 7 7 7 7 7 7 7 7 7 7 7	100 Odds M-H, r 0.94 (0 5.56 (2 27.92) 1.94 (0 2.72 (0 1.97 (1 40.45 (2.64 (1 1.22 (0 1.23 (0	-13.05 (-19.02, -7.08) ratio Y (random, 95% Cl 	ar 85 00 002 10 12 13 13 13 14 14 14 14 10 07 08 11 11 12 12 13 13 13 13 13 13 13 13 13 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: . Study or subgroup Asian Grange et al ²³ Wilkinson et al ²³ Wilkinson et al ²⁴ Martineau et al ²⁵ Chaudhary et al ²⁹ Joshi et al ²⁶ Joshi et al ²⁶ Chaudhary et al ²⁹ Jubuis et al ²⁷ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=1.50 (Ethnicity and et al ²⁸ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=36$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sita et al ²⁸ Heterogeneity: $r^2=0.16$ (Sita events Heterogeneity: $r^2=0.16$ (Sita et al ²⁸ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.10$; $\chi^2=4.3$	$\begin{array}{c} \text{Fe}(P=0,0001)\\ \text{Fr}(13,86,df=27\\(P=0,0001)\\ \chi^2=1.92,df=2\\ \hline \textbf{B}\\ \textbf{Events}\\ \hline \textbf{9}\\ \text{69}\\ 16\\ 60\\ 8\\ 42\\ 73\\ 11\\ 11\\ 83\\ 33\\ 455\\ 51\\ 11\\ 13\\ 6\\ (P=0,0001)\\ \hline \textbf{31}\\ 31\\ 6\\ 155\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 1$	Control (P < 0.000) r (P < 0.00)	01); <i>P</i> =91 0001); <i>P</i> = C C C C C C C C C C	383 % 3,599 996% control vents 1 1 1 1 4 1 9 9 9 9 17 5 9 7 5 6 5 3 7 7 5 6 5 3 3 2	Total 38 42 16 16 55 219 85 25 282 118 1,163 494 115 50 178 19 43 157 347 1,403 130 72 235	(*) 4.4 4.1 1.1 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 4 4 4 4	3,063 Feight 6) 2 2 8 4 4 0 8 3 4 1 2 8 4 1 2 8 7 7 6 7 7 6 1 2 2 8 7 7 6 1 2 2 8 7 7 6 1 2 8 7 7 6 9 7 7 7 6 9 7 7 7 7 6 9 7 7 7 7 7 7 7 7 7 7 7 7 7	100 Odds M-H, r 0.94 (0 5.56 (2 27.92) 1.94 (0 2.72 (0 1.97 (1 40.45 (2.64 (1 1.22 (0 1.23 (0	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 19 5.0, 12.35) 22 1.55, 501.86) 22 1.52, 501.86) 22 1.52, 501.86) 22 1.52, 501.86) 22 1.52, 501.86) 22 1.53, 4.23) 22 1.54, 575) 22 1.55, 4.32) 22 1.54, 4.23) 22 1.54, 4.25) 22 1.54, 4.23) 22 1.54, 4.25) 22 1.54, 4.23) 22 1.54, 52, 30 2.54, 52 2.54, 54 2.54, 54 2	ar 85 00 02 10 12 13 13 13 14 14 14 14 14 14 11 12 13 13 13 13 13 13 13 13 13 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: . Study or subgroup Asian Grange et al ⁸³ Martineau et al ⁸³ Kim et al ⁸⁵ Chaudhary et al ⁸⁹ Jubuis et al ⁸⁰ Jubuis et al ⁸⁰ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Gioney et al ⁸ Gioney et al ⁸⁵ Gioney et al ⁸⁵ Conesa-Bottella et al ⁸¹² Martineau et al ⁸³ Steenhoff et al ¹¹⁴ Martineau et al ⁸⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sita-Lumsden et al ⁸⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.01$; $\chi^2=4.3$ Fetherogeneity: $r^2=0.01$; $\chi^2=4.3$ Fetherogeneity: $r^2=0.01$; $\chi^2=4.3$ Test for overall effect: Z=4.95 ($\begin{array}{c} \text{Fe}(P=0,0001)\\ \text{Fr}(13,86,df=27\\(P=0,0001)\\ \chi^2=1.92,df=2\\ \hline \textbf{B}\\ \textbf{Events}\\ \hline \textbf{9}\\ \text{69}\\ 16\\ 60\\ 8\\ 42\\ 73\\ 11\\ 11\\ 83\\ 33\\ 455\\ 51\\ 11\\ 13\\ 6\\ (P=0,0001)\\ \hline \textbf{31}\\ 31\\ 6\\ 155\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 1$	C < 0.0000 C (P < 0.01) T otal 40 104 362 40 106 107 107 362 40 50 959 959 101 112 122 102 178 72 119 161 122 2,166 0.00001) 178 72 178 22); P = C	01); <i>P</i> =91 0001); <i>P</i> =91 0001); <i>P</i> =0% C E 9 9 1: 0 0 3 3 4 4 2: 2 2 2 4 4 4 2: 2 5; 5; 7; 7; 7; 7; 7; 7; 7; 7; 7; 7; 7; 7; 7;	383 % 3,599 996% iontrol vents 1 1 1 1 4 1 9 9 9 9 17 5 5 9 7 5 6 5 37 3 3 3 2 4	Total 38 42 16 55 219 86 197 85 25 282 282 118 1,163 494 115 50 178 19 43 157 347 1,403 130 72 236 255 693	(°) 4. 4. 1. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 44 4. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 reight 6 2 2 4 4 0 8 3 4 4 1 2 2 8 7 6 7 7 6 6 7 7 6 1 2 4 2 8 7 7 6 6 7 7 7 6 1 2 8 7 7 7 6 6 1 1 1 2 8 7 7 7 7 7 7 7 7 7 7 7 7 7	100 Odds i M-H, r 0.94 (0 5.56 (2 2.7.92 (1 1.94 (0 2.72 (0 2.72 (0 1.94 (0 2.72 (0 2.72 (1 1.92 (1 2.62 (1 0.62 (0 1.92 (1 1.22 (0 2.62 (1 1.92 (1 1.23 (0 5.49 (2 1.94 (0 2.62 (1 1.94 (1 1.22 (0 2.62 (1 1.94 (1 1.22 (0 2.62 (1 1.94 (1 3.55 (0 1.84 (1 3.55 (0 2.71 (1 3.55 (2 2.71 (1 3.55 (2	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 1.33, 2.68) 19 5.0, 12.35) 20 1.55, 501.86) 20 1.55, 501.86) 20 1.55, 501.86) 20 2.53, 55) 20 2.63, 2.63) 20 2.22, 737.97) 20 3.3, 5.22) 20 1.66, 2.28) 20 1.63, 4.23) 20 1.39, 0.97) 20 1.39, 0.97) 20 1.39, 0.97) 20 1.34, 5, 8.75) 20 1.35, 4.32) 20 1.35, 4.33) 20 1.35, 10.76) 20 1.25, 10.760 2	ar 85 00 02 10 12 13 13 13 14 14 14 14 14 14 11 12 13 13 13 13 13 13 13 13 13 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: Study or subgroup Asian Grange et al ⁴³ Martineau et al ⁴⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Test for overall effect: Z=3.96 (African Weijse et al ⁴⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=50$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sita-Lumsden et al ⁴⁶ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=50$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sita-Lumsden et al ⁴⁶ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.10$; $\chi^2=4.3$ Total (95% CI)	$\begin{array}{c} \text{F69.26, } df = 6 \ (F \\ (P < 0.0001) \end{array} \\ \text{F713.86, } df = 27 \\ (P < 0.0001) \\ \chi^2 = 1.92, \\ df = 27 \\ \chi^2 = 1.92, \\ \chi^2 = 1.92, \\ df = 27 \\ \chi^2 = 1.92, $	Control (P < 0.000) r (P < 0.00)	01); P=91 0001); P= C C C C 9 9 1 1 0 0 2 2 2 2 2 2 2 2 2 2 2 2 2	383 % 3,599 996% iontrol vents 1 1 1 1 4 1 9 9 9 7 5 9 7 5 9 7 5 6 5 3 7 7 5 6 3 3 7 3 2 4 10	Total 38 42 16 16 55 219 85 25 282 118 1,163 494 115 50 178 19 43 157 347 1,403 130 72 235	(°) 4. 4. 1. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 44 4. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 Feight 6) 2 2 8 4 4 0 8 3 4 1 2 8 4 1 2 8 7 7 6 7 7 6 1 2 2 8 7 7 6 1 2 2 8 7 7 6 1 2 8 7 7 6 9 7 7 7 6 9 7 7 7 7 6 9 7 7 7 7 7 7 7 7 7 7 7 7 7	100 Odds i M-H, r 0.94 (0 5.56 (2 2.7.92 (1 1.94 (0 2.72 (0 2.72 (0 1.94 (0 2.72 (0 2.72 (1 1.92 (1 2.62 (1 0.62 (0 1.92 (1 1.22 (0 2.62 (1 1.92 (1 1.23 (0 5.49 (2 1.94 (0 2.62 (1 1.94 (1 1.22 (0 2.62 (1 1.94 (1 1.22 (0 2.62 (1 1.94 (1 3.55 (0 1.84 (1 3.55 (0 2.71 (1 3.55 (2 2.71 (1 3.55 (2	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 3.3, 2.68) 19 5.0, 12.35) 22 1.55, 501.86) 22 1.52, 501.86) 22 1.52, 501.86) 22 1.52, 501.86) 22 1.52, 501.86) 22 1.53, 4.23) 22 1.54, 575) 22 1.55, 4.32) 22 1.54, 4.23) 22 1.54, 4.25) 22 1.54, 4.23) 22 1.54, 4.25) 22 1.54, 4.23) 22 1.54, 52, 30 2.54, 52 2.54, 54 2.54, 54 2	ar 85 00 02 10 12 13 13 13 14 14 14 14 14 14 11 12 13 13 13 13 13 13 13 13 13 13	Lower Lower vit D in TB vit D in control Odds ratio
Subtotal (95% CI) Heterogeneity: $r^2=129.43$; $\chi^2=1$ Test for overall effect: Z=3.90 (Total (95% CI) Heterogeneity: $r^2=235.82$; $\chi^2=1$ Test for overall effect: Z=4.28 (Test for subgroup differences: . Study or subgroup Asian Grange et al ⁸³ Martineau et al ⁸³ Kim et al ⁸⁵ Chaudhary et al ⁸⁹ Jubuis et al ⁸⁰ Jubuis et al ⁸⁰ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.41$; $\chi^2=35$ Gioney et al ⁸ Gioney et al ⁸⁵ Gioney et al ⁸⁵ Conesa-Bottella et al ⁸¹² Martineau et al ⁸³ Steenhoff et al ¹¹⁴ Martineau et al ⁸⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=1.23$; $\chi^2=80$ Test for overall effect: Z=1.50 (Ethnicity unspecified Sita-Lumsden et al ⁸⁵ Subtotal (95% CI) Total events Heterogeneity: $r^2=0.01$; $\chi^2=4.3$ Fetherogeneity: $r^2=0.01$; $\chi^2=4.3$ Fetherogeneity: $r^2=0.01$; $\chi^2=4.3$ Test for overall effect: Z=4.95 ($\begin{array}{c} \text{Fe}(P < 0, 0001) \\ \text{FT}(P < 0, 0001) \\ \text{FT}(P < 0, 0001) \\ \chi^2 = 1.92, df = 2 \\ \hline \text{Events} \\ \hline 9 \\ \text{FS} \\ \text{Events} \\ \hline 9 \\ \text{FS} \\ \text{FS}$	C < 0.0000	01); <i>P</i> =91 0001); <i>P</i> =91 0001); <i>P</i> = C E B C C C C C C C C	383 % 3,599 996% 11 1 1 1 1 1 1 1 1 1 1 9 99 9 17 5 9 7 5 6 5 7 7 6 6 5 37 3 3 3 2 4 10	Total 38 42 16 55 219 86 197 85 25 282 282 118 1,163 494 115 50 178 19 43 157 347 1,403 130 72 236 255 693	(°) 4. 4. 1. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 44 4. 3. 3. 3. 3. 3. 3. 3. 3. 3. 3. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	3,063 reight 6 2 2 4 4 0 8 3 4 4 1 2 2 8 7 6 7 7 6 6 7 7 6 1 2 4 2 8 7 7 6 6 7 7 7 6 1 2 8 7 7 7 6 6 1 1 1 2 8 7 7 7 7 7 7 7 7 7 7 7 7 7	100 Odds i M-H, r 0.94 (0 5.56 (2 2.7.92 (1 1.94 (0 2.72 (0 2.72 (0 1.94 (0 2.72 (0 2.72 (1 1.92 (1 2.62 (1 0.62 (0 1.92 (1 1.22 (0 2.62 (1 1.92 (1 1.23 (0 5.49 (2 1.94 (0 2.62 (1 1.94 (1 1.22 (0 2.62 (1 1.94 (1 1.22 (0 2.62 (1 1.94 (1 3.55 (0 1.84 (1 3.55 (0 2.71 (1 3.55 (2 2.71 (1 3.55 (2	-13.05 (-19.02, -7.08) ratio Ye andom, 95% CI 1.33, 2.68) 19 5.0, 12.35) 20 1.55, 501.86) 20 1.55, 501.86) 20 1.55, 501.86) 20 2.53, 55) 20 2.63, 2.63) 20 2.22, 737.97) 20 3.3, 5.22) 20 1.66, 2.28) 20 1.63, 4.23) 20 1.39, 0.97) 20 1.39, 0.97) 20 1.39, 0.97) 20 1.34, 5, 8.75) 20 1.35, 4.32) 20 1.35, 4.33) 20 1.35, 10.76) 20 1.25, 10.760 2	ar 85 000 002 101 102 133 133 14 14 007 008 111 112 122 123 133 13 14 14 07 07 10 112 13 13 13 14 14 14 15 15 15 15 15 15 15 15 15 15	Lower Lower vit D in TB vit D in control Odds ratio

Figure 2 (A) Forest plot of comparison of vitamin D level (serum 25-hydroxyvitamin D [25(OH)D]) in TB patients vs control: overall effect for continuous outcome using a random-effect model. (B) Forest plot of association between VDD and risk of TB: overall effect for dichotomous outcome using a random-effect model. The diamonds stand for pooled effect.

Abbreviations: TB, tuberculosis; vit, vitamin; VDD, vitamin D deficiency; SD, standard deviation; CI, confidence interval; df, degrees of freedom; IV, independent variable.

difference for the African population (MD =-6.05; 95% CI =[-20.54, -8.43]; *P*=0.41; *I*²=98) (Figure 2A). We found a similar result when the same analysis was performed excluding studies where cases and controls were subjects with other diseases such as HIV and diabetes, or where control subjects had LTBI (data not shown).

For our analysis on VDD and risk of TB, a total of 23 studies with 3,491 TB cases and 3,259 control subjects were included (Figure 2B).^{1,2,4,5,11,12,14,23,28,30,32–37,39,40–43,46,47} Our analysis showed that VDD was significantly associated with an increased risk of TB (OR =2.57; 95% CI =[1.74, 3.80]; P < 0.00001; I^2 =83) (Figure 2B). Subgroup analysis revealed similar result for the Asian population (OR =2.62; 95% CI =[1.63, 4.23]; P < 0.0001; I^2 =71); however, VDD was not associated with an increased risk of TB in the African population (OR =1.89; 95% CI =[0.82, 4.33]; P=0.13; I^2 =91) (Figure 2B). Results were similar when the same analysis was performed excluding studies where

cases and controls were subjects with other diseases such as HIV and diabetes, or where control subjects had LTBI (data not shown).

VDD was more likely a risk factor for TB than its consequence

Four studies with 331 active TB cases and 326 LTBI subjects/ household contacts of active TB patients were included in our meta-analysis (Figure 3A).^{4,35,36,42} We included household contacts of active TB patients as part of our control in this analysis because they were at a high risk of becoming infected and developing TB,⁴² and a meta-analysis by Fox et al⁵³ reported a high prevalence of LTBI in contacts of active TB patients (51.5%; 95% CI =[47.1%, 55.8%]; P=98.9%). Our analysis revealed a trend toward a lower serum/plasma 25(OH)D level in active TB patients vs LTBI subjects/household contacts of active TB patients; however, this trend did not reach the level of statistical




Figure 3 (A) Forest plot of comparison of serum 25(OH)D level in active TB patients vs LTBI subjects/household contacts of active TB patients: overall effect for continuous outcome using a random-effect model. (B) Forest plot of association between VDD and risk of developing active TB in LTBI subjects or household contacts of TB patients: overall effect for dichotomous outcome using a random-effect model. (C) Forest plot of association between VDD and risk of TST conversion/TBIC: overall effect for dichotomous outcome using a fixed-effect model. The diamonds stand for pooled effect.

Abbreviations: TB, tuberculosis; LTBI, latent TB infection; vit, vitamin; VDD, vitamin D deficiency; TST, tuberculin skin test; TBIC, TB infection conversion; SD, standard deviation; CI, confidence interval; *df*, degrees of freedom; IV, independent variable.

significance (MD =-8.92; 95% CI =[-18.62, 0.79]; *P*=0.07; *P*=90) (Figure 3A).

VDD was significantly associated with an increased risk of developing active TB in LTBI subjects/ household contacts of TB patients

Five studies with 372 active TB patients and 407 LTBI subjects/household contacts of active TB patients were included in our analysis (Figure 3B).^{2,4,35,36,42} VDD was positively and significantly associated with an increased risk of developing active TB in LTBI subjects/household contacts of active TB patients (OR =4.26; 95% CI =[2.48, 7.30]; P < 0.00001; P = 48%) (Figure 3B).

VDD was significantly associated with an increased risk of TST conversion/TBIC

Our meta-analysis here included three studies with 45 cases with TST conversion/TBIC and 366 control subjects without

TST conversion/TBIC (Figure 3C).^{48–50} Our analysis using a fixed-effect model revealed significant association between VDD and an increased risk of TST conversion/ TBIC (OR =3.99; 95% CI =[1.88, 8.45]; P=0.0003; P=0) (Figure 3C).

Vitamin D, TB, and HIV

No significant vitamin D level difference in HIV-TBcoinfected African patients vs African HIV patients without active TB, and VDD was not associated with an increased risk of TB in African HIV-infected patients

Our meta-analysis comparing vitamin D level in HIV-TB-coinfected patients vs HIV patients without active TB included four studies on the African population with 260 HIV-TB-coinfected cases and 164 control HIV subjects without active TB (Figure 4A).^{11,12,14,35} Serum/plasma 25(OH)D level in HIV-TB-coinfected African patients was not

Α	Study or subgroup		TB Mean	SD	Total	Contr Mean		Total		Mean difference IV, random, 95% CI	Year	Mean differen random, 95%	
	African Nansera et al ¹⁴ Martineau et al ³⁵ HIV-infec Steenhoff et al ¹¹ Conesa-Botella et al ¹² HIV- Subtotal (95% CI)	-infected		27.5 19.1 11.19 32.59	92 260	70 54.7 38.3 79	27.5 27.4 10.15 28.15		24.3 26.8 27.1 21.8 100	-10.00 (-20.78, 0.78) -26.00 (-33.25, -18.75) -3.20 (-9.99, 3.59) 2.00 (-12.02, 16.02) -9.83 (-22.87, 3.22)	2011 2011 2012 2012	++ + +	
	Heterogeneity: τ^2 =151.71; Test for overall effect: Z=1			(P<0.0	001); <i>I</i> 2	=88%							
	Total (95% CI) Heterogeneity: <i>τ</i> ² =151.71;	χ²=24.71	, df=3	(<i>P</i> <0.0	260 01); /2=	88%		164	100	-9.83 (-22.87, 3.22)	F	-	
	Test for overall effect: Z=1. Test for subgroup difference	`	,	le							-100		50 100 Lower vit D in HIV
в	Study or subgroup		TB Eve	nts	Total	Con Eve		Total	Weigh (%)	t Odds ratio M–H, random, 95% Cl	Year	Odds ratio N random, 95%	1– H,
	African Martineau et al ³⁵ HIV-infect Nansera et al ¹⁴ Conesa-Botella et al ¹² HIV- Steenhoff et al ¹¹ Subtotal (95% CI)		85 6 15 15		99 50 92 19 260	39 5 3 15		75 50 20 19 164	32.6 24.3 23.0 20.1 100	5.60 (2.72, 11.56) 1.23 (0.35, 4.32) 1.10 (0.29, 4.24) 1.00 (0.21, 4.76) 1.89 (0.69, 5.14)	2011 2011 2012 2012		-
	Total events Heterogeneity: τ^2 =0.67; χ^2 Test for overall effect: Z=1			0.03); <i>I</i>	²=65%	62							
	Total (95% CI) Total events		121		260	62		164	100	1.89 (0.69, 5.14)			-
	Heterogeneity: τ^2 =0.67; χ^2 Test for overall effect: Z=1. Test for subgroup difference	.24 (P=0.	22)		²=65%						0.01		10 100 DD increased TB risk
С		B-IRIS lean Si	D	Total	Cont Mean		T	otal	Weight (%)	Mean difference IV, fixed, 95% Cl	Year	Mean differen fixed, 95% Cl	ce IV,
		2.5 7. 4.5 33 ==2 (<i>P</i> =0.9	26 3.64 94); /²=	15 23 39 77 ₽0%	65 28 72.1	17. 7.1 20.	9 2 81 5	85 29 33 1 7	5.1 85.6 9.4 100	-5.00 (-21.25, 11.25) -5.50 (-9.46, -1.54) -7.60 (-19.55, 4.35) -5.67 (-9.33, -2.01)	2011 2012 2012	•	
	Total (95% CI) Heterogeneity: χ^2 =0.11, <i>df</i> Test for overall effect: <i>Z</i> =3 Test for subgroup difference	=2 (P=0.9 .04 (P=0.1	94); /²= 002)				1	17	100	-5.67 (-9.33, -2.01)	⊢ −100 Vit	→ → → → → → → → → → → → → →	50 100 D increased risk

Figure 4 (A) Forest plot of comparison of serum 25(OH)D level in HIV-TB-coinfected patients vs HIV patients without active TB: overall effect for continuous outcome using a random-effect model. (B) Forest plot of association between VDD and risk of TB in HIV-infected patients: overall effect for dichotomous outcome using a random-effect model. (C) Forest plot comparing 25(OH)D level in HIV-TB-coinfected patients receiving ART who developed TB-IRIS vs HIV-TB-coinfected patients receiving ART who did not develop TB-IRIS: overall effect for continuous outcome using a fixed-effect model. The diamonds stand for pooled effect.

Abbreviations: HIV, human immunodeficiency virus; TB, tuberculosis; ART, antiretroviral therapy; TB-IRIS, TB-associated immune reconstitution inflammatory syndrome; vit, vitamin; VDD, vitamin D deficiency; SD, standard deviation; CI, confidence interval; *df*, degrees of freedom; IV, independent variable.

significantly different from HIV-infected African patients without active TB (MD =–9.83; 95% CI =[-22.87, 3.22]; P=0.14; I²=88) (Figure 4A).

The same four studies on African population with 260 HIV-TB-coinfected cases and 164 control HIV subjects without active TB were included in our analysis on the association between VDD and risk of TB in HIV-infected patients (Figure 4B).^{11,12,14,35} There was no significant association between VDD and risk of TB in African HIV-infected patients (OR =1.89; 95% CI =[0.69, 5.14]; *P*=0.22; I^2 =65) (Figure 4B).

Significantly lower vitamin D level in HIV-TBcoinfected African patients receiving ART who developed TB-IRIS vs those who did not develop TB-IRIS

Three studies with 77 HIV-TB-coinfected African cases receiving ART who developed TB-IRIS and 117 African control patients who did not develop TB-IRIS were included in this analysis (Figure 4C).^{12,14,51} HIV-TB-coinfected African cases receiving ART who developed TB-IRIS had a significantly lower vitamin D level vs those who did not develop TB-IRIS (MD =–5.67; 95% CI =[–9.33, –2.01]; P=0.002; I^2 =0) (Figure 4C).

Anti-TB treatment and vitamin D level Anti-TB treatment did not affect vitamin D level in TB patients receiving the treatment

Three studies with 224 TB patients receiving 1–4 months of anti-TB treatments^{25,37,52} and four studies with 391 TB patients receiving full course of anti-TB treatment^{1,25,37,46} were included in our analysis on whether anti-TB treatment affected vitamin D level in TB patients receiving the treatment (Figure 5A and B). Neither 1–4 months of anti-TB treatment (MD=1.47; 95% CI=[-2.79, 5.73]; P=0.50; P=57) (Figure 5A) nor a full course of anti-TB treatment (MD=5.03; 95% CI=[-3.20, 13.25]; P=0.23; P=86) (Figure 5B) affected 25(OH)D level significantly.

TB patients still had a significantly lower vitamin D level after completion of anti-TB treatment than controls without TB

Four studies with 327 TB cases after completion of anti-TB treatment and 592 control subjects without TB were included (Figure 5C).^{1,25,37,46} Vitamin D level was still significantly lower in TB patients after completion of their anti-TB treatment vs control subjects without TB (MD =–8.05; 95% CI =[-13.56, -2.54]; P=0.004; I^2 =68) (Figure 5C), especially for the Asian population

(MD =-9.36; 95% CI =[-15.23, -3.48]; *P*=0.002; *I*²=80) (Figure 5C).

A trend of higher 1,25(OH)2D3 level in TB patients vs controls without TB

Although serum 25(OH)D is the commonly used measure of vitamin D status in a subject,⁷ 1,25(OH)2D3 is the actual bioactive form of vitamin D that induces antimicrobial response,⁷ and therefore we performed a meta-analysis comparing 1,25(OH)2D3 level in TB subjects vs controls without TB. Four studies with 160 TB cases and 338 control subjects without TB were included (Figure 6).^{22,29,31,45} There was a trend toward higher 1,25(OH)2D3 level in TB patients vs controls; however, this trend did not reach the level of statistical significance (SMD =1.02; 95% CI =[-0.09, 2.14]; P=0.07; l^2 =95) (Figure 6).

Between-studies heterogeneity and publication bias

Between-studies heterogeneity varied from none to high for our meta-analyses with l^2 values ranging from 0 to 96 (Figures 2A and B, 3A–C, 4A–C, 5A–C, and 6). Furthermore, funnel plots for all of our meta-analyses were symmetrical, suggesting the presence of none or very little publication bias in our analyses (data not shown).

Discussion

Our meta-analysis on the association between vitamin D and TB showed a significantly lower level of vitamin D in TB patients vs controls and that VDD was positively associated with an increased risk of TB, which is consistent with the results of the meta-analysis by Nnoaham et al.¹³ In the subgroup analysis, although we found similar results for the Asian population, such an association was lacking in the African population even when we excluded studies where cases and controls had other diseases such as HIV and diabetes, or where the control subjects had LTBI. This suggested the possibility of ethnic difference in the role of vitamin D in TB that warrants further investigation. As sunlight and diet are two major sources of vitamin D for humans,13 adequate exposure to sunlight and/or adjustment of diet to maintain proper vitamin D level in our bodies is be deemed a necessity.

As HIV-infected subjects are more susceptible to TB and have greater mortality and morbidity caused by TB,¹⁴ in order to further clarify whether vitamin D played any role in occurrence and deterioration of TB in HIV-infected subjects, we also analyzed the association between vitamin D level/ VDD and TB in HIV-infected subjects and the association

												5
Davies et al ²⁵ patient group Oct to Mar	21.75 8 16	8.88	4 6	22 14 25 1	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	14	15.9	-0.25 (-8.93, 8.43) 1 75 (-0.03 3 53)	1987 1987		ł	
	.							10.10 (1.52, 18.68)	2010		1	
		21.04	116	75		116 2		-3.50 (-9.32, 2.32)	2012		ŧ	
Total (95% Cl)	į		224		8	224 1	100	1.47 (–2.79, 5.73)	-	-	•	-
Heterogenerty. <i>r</i> = 10.13; <i>x</i> ⁼⁶ .35, <i>d</i> =3 (<i>r</i> =5.0/); <i>r</i> =5.1% Test for overall effect: Z=0.68 (<i>P</i> =0.50)	:(/0.0=~	%/G=≠/							T 01	00 –50 Treatment decreased vit D	- 0	50 100 Treatment increased vit D
Study or subgroup	After treatment Mean SD	atment SD 1	Total	Before treatment Mean SD To	treatment SD T	otal	Weight N (%)	Mean difference IV, random, 95% Cl	Year	22	Mean difference IV, random, 95% CI	e % CI
Asian												
	27.5	17.28	116	75				-7.25 (-12.64, -1.86) 2012) 2012		ŧ	
Kim et al ^{to} Hond et al ⁴⁶		19.03 1 16.87 5		33 2 28.5 1	21.58 1	165 2 83	24.8	-1.50 (-5.89, 2.89) 4 45 (-0.35, 9.25)	2013 2014		+ +	
5% CI) ty: r^2 =24.92; χ^2 =10.17, df =2 all effect: Z=0.42 (P =0.68)	(P=0.00	6); /2=80	8					-1.34 (-7.65, 4.97)			•	
Ethnicity												
	30	31.56	13	.25	6			15.75 (-1.42, 32.92)	1987		1	
Davies et al∞ patient group Oct to Mar Subtotal (95% CI)			4 C	77	14 2 - 2	27 14 1	26.7 26.7	28.50 (13.77, 43.23) 22 92 (10 52, 35.32)	1987			
Heterogeneity: $r^2 = 14.69$; $\chi^2 = 1.22$, $df = 1$ (P=0.27); $P = 18\%$ Test for overall effect: Z=3.62 (P=0.0003)	P=0.27);	<i>P</i> =18%	i		I							
			3		č							
lotal (95% Cl) Heteroneneity∵ ㎡=65 99: ☆²=28 25	100 0>d)	01) /2=8	391 86%		n	1 185	<u>001</u>	o.u3 (-3.20, 13.25)	-	_		_
Test for subgroup effects: $Z=1,2$, $Z=2,2,3$, $Z=2,2,2,3$, $Z=2,2,2,2,3$, $Z=2,2,2,2,3$, $Z=2,2,2,2,3$, $Z=2,2,2,2,3$, $Z=2,2,2,2,2,3$, $Z=2,2,2,2,2,2,2,2,2,2,2,2$	// -0.00 df=1 (P=	0.0006);	/2=91.4	%					-100	00 –50 Treatment decreased vit D	- 0	50 100 Treatment increased vit D
Study or	E			Control	_		Weint	ht Mean difference	a	Year	dean di	
٩	Mean	SD	Total	Mean	SD	Total	(%)		% CI		IV, random, 95% CI	1, 95% CI
Asian Koo et al [™] 27.5 17.28 Kin et al [™] 31.25 19.03 Hong et al [™] 32.95 16.87 Subtotal 95% CI) Heterogeneity: r ⁼ =21.56; x ²⁼ 10.04, df=2 (P=0.007); l ² =80% Test for overall effect: Z=3.12 (P=0.002)	27.5 31.25 32.95 ? (P=0.00	17.28 19.03 16.87 7); /²=80º	116 101 83 300	33 46.75 40.08	17.96 20.83 14.67	86 197 282 565	28.5 29.1 30 .9 88.5	-5.50 (-10.43, -0.57) -15.50 (-20.22, -10.78) -7.13 (-11.14, -3.12) -9.36 (-15.23, -3.48)	-0.57) -10.78) -3.12) -3.48)	2012 2013 2014	****	
			5	ç		9	0					
nt group Apr-Sep nt group Oct to Mar	30 50.5	31.50 24.38	<u>5</u> 4	46 46	37.5 23.5	5 4	3.8 7.7	–3.00 (–29.04, 23.04) 4.50 (–13.24, 22.24)	23.04) 2.24)	1987 1987		
Subtotal (95% Cl) Heterogeneity: $r^{=}0.00$; $\chi^{2}=0.21$, $df=1$ ($P=0.65$); $\beta=0\%$ Test for overall effect: $Z=0.29$ ($P=0.77$)	=0.65); /	%0= ₂	27			27	11.5	2.20 (-12.57, 11	9 . 96)		V	•
Total (95% CI)		1	327			592	100	-8.05 (-13.56, -2.54)	-2.54)	_	•	_
Heterogeneity: r*=21.40; x*=12.48, d*=4 (P=0.01); r*=68% Test for overall effect: Z=2.88 (P=0.004) Test for subaround differences: r*=2.03, d/=1 (P=0.15); r*=50.7%	(P=0.01 f=1 (P=0); /²=68% 1.15): /²=:	6 50.7%							-100 -50 I ower vit D in TB	- o	50 100 100 100 100 100 100 100 100 100 1

Figure 5 (A) Forest plot of the effect of 1-4 months of anti-TB treatment on vitamin D level (25(OH)D) in TB patients: overall effect for contin anti-TB treatment on vitamin D level (25(OH)D) in TB patients: overall effect for continuous outcome using a random-effect model. (C) Forest control without TB: overall effect for continuous outcome using a random-effect model. The diamonds stand for pooled effect. Abbreviations: TB, tuberculosis; SD, standard deviation; CI, confidence interval; vit, vitamin; df, degrees of freedom; IV, independent variable.

Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 208.53.112.118 on 30-Dec-2016 For personal use only.

Study or subgroup	TB Mean	SD	Total	Contro Mean		Total	Weight (%)	Std mean difference IV, random, 95% CI	Year	Std mean IV, randon	difference n, 95% Cl	
Asian							. ,			,		
Yonemura et al ²⁹	45.9	31.5	6	11.8	7.5	110	22.7	3.43 (2.50, 4.37)	2004		•	
Selvaraj et al ³¹	92.5	50.39	65	62.5	43.78	60	26.4	0.63 (0.27, 0.99)	2009			
Gao et al45	365.9	235.7	74	464.3	335.6	153	26.7	-0.32 (-0.60, -0.04)	2014			
Subtotal (95% C	I)		145			323	75.8	1.16 (-0.24, 2.55)			•	
Heterogeneity: τ^{2} Test for overall eff				><0.0000	01); /²=9	7%						
Ethnicity unspec	cified											
Davies et al22	35.7	10.48	15	28.7	9.75	15	24.2	0.67 (-0.07, 1.41)	1985			
Subtotal (95% C	I)		15			15	24.2	0.67 (-0.07, 1.41))	
Heterogeneity: no Test for overall eff			0.07)									
Total (95% CI)			160			338	100	1.02 (-0.09, 2.14)				
Heterogeneity: τ^2 Test for overall eff	fect: Z=1	.81 (P=	0.07)						⊢ –100	-50 (D 50	
Test for subgroup	differen	ces: χ ² =	0.36, df	=1 (<i>P</i> =0	.55); /²=	0%				Lower 1,25(OH)2D3 in TB	Higher 1,25(OH)2D3 in TB	

Figure 6 Forest plot of comparison of the level of the vitamin D metabolite – serum/plasma 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in TB patients vs control without TB: overall effect for continuous outcome using a random-effect model.

Note: The diamonds stand for pooled effect.

Abbreviations: TB, tuberculosis; SD, standard deviation; Cl, confidence interval; df, degrees of freedom; IV, independent variable.

between vitamin D level and risk of developing TB-IRIS in HIV-TB-coinfected patients receiving ART. Our analysis showed that there was no significant difference in vitamin D level in HIV-TB-coinfected African patients vs African HIV patients without active TB and that VDD was not associated with an increased risk of TB in African HIV-infected patients. However, a significantly lower vitamin D level was found in HIV-TB-coinfected African patients receiving ART who developed TB-IRIS vs those who did not. In view of the fact that our analysis showed lack of association between vitamin D and TB in the African population, such lack of association between vitamin D and TB in the HIV-infected African population should be interpreted with caution as to whether it represents a true lack of association in HIV-infected subjects; studies on HIV-infected subjects of other ethnicities are needed to confirm these results. However, if such a lack of association is indeed true, Steenholf et al¹¹ suggested that as HIV-infected subjects are already immunocompromised, it is possible that any immune response induced by vitamin D would also be compromised, thus masking any role vitamin D played in fighting TB; this, along their observation that HIV-infected subjects without TB were already plagued with VDD, could provide a possible explanation for such a lack of association between vitamin D and TB in HIV-infected subjects. On the other hand, our finding that HIV-TB-coinfected subjects who developed TB-IRIS (a paradoxical worsening of TB after initial improvement upon TB treatment after ART initiation or manifestation of TB clinically not apparent before ART initiation) had a lower vitamin D level that those who did not suggest that vitamin D was somehow still involved

in TB occurrence and progression in HIV-infected patients. Conesa-Botella et al⁵¹ reported an association between VDD and elevated proinflammatory cytokine and that corticosteroid therapy could modify patients' inflammatory profile and possibly even reduce the severity of TB-IRIS symptom and suggested vitamin D supplement prior to ART initiation to determine whether it decreased TB-IRIS incidence. Meanwhile, as only a limited number of studies with limited sample sizes were included in our analyses, more studies with larger sample sizes are needed to further elucidate whether there is any association between VDD and TB/TB-IRIS.

Also, our analysis found a significant association between VDD and TB, but it did not tell us whether VDD was a risk factor or a consequence of TB; however, our analysis revealed that VDD was significantly associated with an increased risk of developing active TB in LTBI subjects/household contacts of TB patients, that VDD was significantly associated with an increased risk of TST conversion/TBIC, and that the trend toward a lower vitamin D level in active TB patients vs LTBI subjects/household contacts of active TB patients did not reach statistical significance. These results suggested that VDD was more likely a risk factor for TB rather than its consequence. Had VDD been a manifestation of malnutrition generally associated with TB, we would expect a more significant difference in vitamin D level between active TB patients vs LTBI subjects/household contacts of active TB patients and VDD would not have been significantly associated with an increased risk of LTBI developing into active TB or TST conversion/TBIC. On the contrary, our result suggested that vitamin D was possibly involved in the early stage of TB infection and symptom manifestation; in addition, it has been shown that 1,25(OH)2D3 activates VDR signaling and induces antimicrobial responses such as induction of autophagy, phagolysosomal fusion, release and activation of the antimicrobial peptide cathelicidin, and killing of intracellular M. tuberculosis.7-9 All of these results pointed to the fact that VDD is more likely a risk factor for TB. This possibility was further strengthened by our results that anti-TB treatment did not significantly affect vitamin D level in TB patients receiving the treatment and that TB subjects after completion of anti-TB treatment still had a significantly lower vitamin D level than control subjects without TB. This was because if VDD had been a consequence of TB, we would expect a significantly elevated vitamin D level in TB subjects after effective anti-TB treatment. Overall, our analyses indicated that VDD was most likely a risk factor for TB.

Since our analysis indicated that VDD was most likely a risk factor for TB, this raises a question of whether vitamin D supplement would be beneficial to TB prevention and treatment. The meta-analysis by Xia et al⁵⁴ in 2012 reported that vitamin D supplementation did not show a significant benefit to TB treatment; however, the meta-analysis did not address the question of whether it would be beneficial to TB prevention. Rigorously controlled studies will be needed to further determine whether vitamin D supplementation would be beneficial.

Because 1,25(OH)D3 is the bioactive form of vitamin D,⁷ we also analyzed the level of 1,25(OH)2D3 in TB subjects vs controls and found a trend of higher 1,25(OH)2D3 level in TB patients vs controls without TB. Selvaraj et al³¹ postulated that this possible increase in 1,25(OH)2D3 could be because of CYP27B1 expression upregulation that led to increased conversion of 25(OH)D to 1,25(OH)2D3, which could then cause 25(OH)D deficiency because of its increased use. However, if this is the case, it would mean that VDD would be a consequence of TB rather than one of its causes and would be inconsistent with our previous conclusions. On the other hand, as only four studies with limited sizes were included in our analysis, this result is far from certain, and more studies are needed to confirm or refute this result.

There are certain strengths and limitations in our study. Its strength lies in the fact that it was a comprehensive analysis of multiple aspects of the relationship between vitamin D and TB and helped to answer the question of whether vitamin D was one of the causes or consequences of TB, and our analysis included all relevant available studies of reasonable quality to ensure that the resulting picture was as complete as possible. However, our study also has certain limitations. For some of our analyses, the number of relevant studies was limited and their sample sizes were small, which undoubtedly would affect the certainty of some of our results. Furthermore, because different studies used different standards for VDD, such inconsistency in VDD definition would also affect our results.

Conclusion

Our analyses revealed a significantly lower vitamin D level in TB subjects and that VDD was associated with more risk of TB. VDD is more likely a risk factor for TB than its consequence, and more studies are needed to determine whether vitamin D supplement is beneficial to TB prevention and treatment.

Disclosure

The authors report no conflicts of interest in this work.

References

- Kim JH, Park JS, Cho YJ, et al. Low serum 25-hydroxyvitamin D level: an independent risk factor for tuberculosis? *Clin Nutr.* 2014;33(6): 1081–1086.
- Gibney KB, MacGregor L, Leder K, et al. Vitamin D deficiency is associated with tuberculos and latent tuberculos is infection in immigrants from sub-Saharan Africa. *Clin Infect Dis.* 2008;46(3):443–446.
- Chocano-Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. *Nutr Rev.* 2009;67(5):289–293.
- Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in West London: a case-control study. *Lancet.* 2000; 355(9204):618–621.
- Wejse C, Olesen R, Rabna P, et al. Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls. *Am J Clin Nutr.* 2007;86(5):1376–1383.
- Ustianowski A, Shaffer R, Collin S, Wilkinson RJ, Davidson RN. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. *J Infect*. 2005;50(5):432–437.
- 7. Realegeno S, Modlin RL. Shedding light on the vitamin D-tuberculosis-HIV connection. *Proc Natl Acad Sci U S A*. 2011;108:18861–18862.
- Liu PT, Stenger S, Li H, et al. Toll-like receptors triggering of a vitamin D mediated anti-microbical response. *Science*. 2006;311(5768): 1770–1773.
- Adams JS, Ren S, Liu PT, et al. Vitamin D directed rheostatic regulation of monocyte antibacterial responses. *J Immunol.* 2009;182(7): 4289–4295.
- Friis H, Range N, Pedersen ML, et al. Hypovitaminosis D is common among pulmonary tuberculosis patients in Tanzania but is not explained by the acute phase response. *J Nutr.* 2008;138(12):2474–2480.
- Steenhoff AP, Redwood A, Pettifor JM, et al. Vitamin D status in HIVinfected patients with and without tuberculosis: a pilot study. J Acquir Immune Defic Syndr. 2012;61(2):e21–e23.
- 12. Conesa-Botella A, Goovaerts O, Massinga-Loembé M, et al. Low prevalence of vitamin D deficiency in Ugandan HIV-infected patients with and without tuberculosis. *Int J Tuberc Lung Dis.* 2012;16(11): 1517–1521.
- Nnoaham KE, Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. *Int J Epidemiol.* 2008; 37:(1)113–119.

- **Dove**press
- Nansera D, Graziano FM, Friedman DJ, Bobbs MK, Jones AN, Hansen KE. Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis. *Int J Tuberc Lung Dis.* 2011; 15(11):1522–1527.
- Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], Section 7.7.3.5 Medians and interquartile ranges. The Cochrane Collaboration, 2011. Available from: http://handbook.cochrane.org/
- Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], Section 7.7.3.6 Ranges. The Cochrane Collaboration, 2011. Available from: http:// handbook.cochrane.org/
- Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011], Section 7.7.3.2 Obtaining standard deviations from standard errors and confidence intervals for group means. The Cochrane Collaboration, 2011. Available from: http://handbook.cochrane.org/
- Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in metaanalysis. Ottawa, ON: Ottawa Health Research Institute; 2004.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
- Higgins J, Thompson S, Deeks J, Altman D. Statistical heterogeneity in systematic reviews of clincial trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy. 2002;7(1):51–61.
- Navarro-Mateu F, Escámez T, Koenen KC, Alonso J, Sánchez-Meca J. Meta-analyses of the 5-HTTLPR polymorphism and post-traumatic stress disorder. *PLoS One*. 2013;8(6):e66227.
- Davies PD, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. *Thorax*. 1985;40(8):187–190.
- Grange JM, Davies PD, Brown RC, Woodhead JS, Kardjito T. A study of vitamin D levels in Indonesian patients with untreated pulmonary tuberculosis. *Tubercle*. 1985;66(3):187–191.
- Davies PD, Church HA, Brown RC, Woodhead JS. Raised serum calcium in tuberculosis patients in Africa. *Eur J Respir Dis.* 1987;71(5): 341–344.
- Davies PD, Brown RC, Church HA, Woodhead JS. The effect of antituberculosis chemotherapy on vitamin D and calcium metabolism. *Tubercle*. 1987;68(4):261–266.
- Davies PD, Church HA, Bovornkitti S, Charumilind A, Byrachandra S. Altered vitamin D homeostasis in tuberculosis. *Int Med Thailand*. 1988;4:45–47.
- Chan TY, Poon P, Pang J, et al. A study of calcium and vitamin D metabolism in Chinese patients with pulmonary tuberculosis. *J Trop Med Hyg.* 1994;97(1):26–30.
- Sasidharan PK, Rajeev E, Vijayakumari V. Tuberculosis and vitamin D deficiency. J Assoc Physicians India. 2002;50:554–558.
- Yonemura K, Ohtake T, Matsushima H, Fujigaki Y, Hishida A. High ratio of 1,25-dihydroxyvitamin D3 to parathyroid hormone in serum of tuberculous patients with end-stage renal disease. *Clin Nephrol.* 2004;62(3):202–207.
- Sita-Lumsden A, Lapthorn G, Swaminathan R, Milburn HJ. Reactivation of tuberculosis and vitamin D deficiency: the contribution of diet and exposure to sunlight. *Thorax*. 2007;62(11):1003–1007.
- Selvaraj P, Prabhu Anand S, Harishankar M, Alagarasu K. Plasma 1,25 dihydroxy vitamin D3 level and expression of vitamin d receptor and cathelicidin in pulmonary tuberculosis. *J Clin Immunol*. 2009;29(4):470–478.
- Ho-Pham LT, Nguyen ND, Nguyen TT, et al. Association between vitamin D insufficiency and tuberculosis in a Vietnamese population. *BMC Infect Dis.* 2010;10:306.
- Martineau AR, Leandro AC, Anderson ST, et al. Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. *Eur Respir J.* 2010;35(5):1106–1112.
- Nielsen NO, Skifte T, Andersson M, et al. Both high and low serum vitamin D concentrations are associated with tuberculosis: a case-control study in Greenland. *Br J Nutr.* 2010;104(10):1487–1491.

- Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. *Proc Natl Acad Sci U S A*. 2011;108(47):19013–19017.
- Gray K, Wood N, Gunasekera H, et al. Vitamin D and tuberculosis status in refugee children. *Pediatr Infect Dis J.* 2012;31(5):521–523.
- Koo HK, Lee JS, Jeong YJ, et al. Vitamin D deficiency and changes in serum vitamin D levels with treatment among tuberculosis patients in South Korea. *Respirology*. 2012;17(5):808–813.
- Rathored J, Sharma SK, Singh B, et al. Risk and outcome of multidrugresistant tuberculosis: vitamin D receptor polymorphisms and serum 25(OH)D. *Int J Tuberc Lung Dis.* 2012;16(11):1522–1528.
- Chaudhary S, Thukral A, Tiwari S, Pratyush DD, Singh SK. Vitamin D status of patients with type 2 diabetes and sputum positive pulmonary tuberculosis. *Indian J Endocrinol Metab.* 2013;17(Suppl 3):S670–S673.
- Friis H, Range N, Changalucha J, et al. Vitamin D status among pulmonary TB patients and non-TB controls: a cross-sectional study from Mwanza, Tanzania. *PLoS One*. 2013;8(12):e81142.
- Iftikhar R, Kamran SM, Qadir A, Haider E, Bin Usman H. Vitamin D deficiency in patients with tuberculosis. *J Coll Physicians Surg Pak*. 2013;23(10):780–783.
- 42. Joshi L, Ponnana M, Penmetsa SR, Nallari P, Valluri V, Gaddam S. Serum vitamin D levels and VDR polymorphisms (BsmI and FokI) in patients and their household contacts susceptible to tuberculosis. *Scand J Immunol.* 2014;79(2):113–119.
- 43. Mastala Y, Nyangulu P, Banda RV, Mhemedi B, White SA, Allain TJ. Vitamin D deficiency in medical patients at a central hospital in Malawi: a comparison with TB patients from a previous study. *PLoS One*. 2013; 8(3):e59017.
- 44. Srinivasan A, Syal K, Banerjee D, et al. Low plasma levels of cholecalciferol and 13-cis-retinoic acid in tuberculosis: implications in host-based chemotherapy. *Nutrition*. 2013;29(10):1245–1251.
- 45. Gao WW, Wang Y, Zhang XR, et al. Levels of 1,25(OH)2D3 for patients with pulmonary tuberculosis and correlations of 1,25(OH)2D3 with the clinical features of TB. *J Thorac Dis.* 2014;6(6):760–764.
- Hong JY, Kim SY, Chung KS, et al. Association between vitamin D deficiency and tuberculosis in a Korean population. *Int J Tuberc Lung Dis.* 2014;18(1):73–78.
- Jubulis J, Kinikar A, Ithape M, et al. Modifiable risk factors associated with tuberculosis disease in children in Pune, India. *Int J Tuberc Lung Dis.* 2014;18(2):198–204.
- Arnedo-Pena A, Juan-Cerdán JV, Romeu-Garcia A, et al. Latent tuberculosis infection, tuberculin skin test and vitamin D status in contacts of tuberculosis patients: a cross-sectional and case-control study. *BMC Infect Dis.* 2011;11:349.
- Ganmaa D, Giovannucci E, Bloom BR, et al. Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial. *Am J Clin Nutr.* 2012;96(2):391–396.
- Arnedo-Pena A, Juan-Cerdán JV, Romeu-García MA, et al. Vitamin D status and incidence of tuberculosis infection conversion in contacts of pulmonary tuberculosis patients: a prospective cohort study. *Epidemiol Infect*. 2015;143(8):1731–1741.
- 51. Conesa-Botella A, Meintjes G, Coussens AK, et al. Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome. *Clin Infect Dis.* 2012;55(7):1004–1011.
- Tostmann A, Wielders JP, Kibiki GS, Verhoef H, Boeree MJ, van der Ven AJ. Serum 25-hydroxy-vitamin D3 concentrations increase during tuberculosis treatment in Tanzania. *Int J Tuberc Lung Dis.* 2010;14(9): 1147–1152.
- Fox GJ, Barry SE, Britton WJ, Marks GB. Contact investigation for tuberculosis: a systematic review and meta-analysis. *Eur Respir J.* 2013; 41(1):140–156.
- 54. Xia J, Shi L, Zhao L, Xu F. Impact of vitamin D supplementation on the outcome of tuberculosis treatment: a systematic review and meta-analysis of randomized controlled trials. *Chin Med J (Engl)*. 2014;127(17): 3127–3134.

- Kim JH, Park JS, ChoYJ, et al. Low serum 25-hydroxyvitamin D level: an independent risk factor for tuberculosis? *Clin Nutr.* 2014;33(6): 1081–1086 (Epub 2013 Nov 26).
- Joshi L, Ponnana M, Penmetsa SR, Nallari P, Valluri V, Gaddam S. Serum vitamin D levels and VDR polymorphisms (BsmI and FokI) in patients and their household contacts susceptible to tuberculosis. *Sand J Immunol.* 2014;79:113–119 (Epub 2013).
- 57. Arnedo-Pena A, Juan Cerdan JV, Romeu-Garcia A, et al. Latent tuberculosis infection, tuberculin skin test and vitamin D status in contacts of tuberculosis patients: a cross-sectional and case-control study. *BMC Infect Dis.* 2011;11:349.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are the features of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

 $\textbf{Submit your manuscript here:} \ \texttt{http://www.dovepress.com/drug-design-development-and-therapy-journal}$

Dovepress